fluconazole has been researched along with Candidiasis, Vulvovaginal in 287 studies
Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.
fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.
Candidiasis, Vulvovaginal: Infection of the VULVA and VAGINA with a fungus of the genus CANDIDA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Oral fluconazole use during the first trimester of pregnancy was marginally associated with an increased risk of congenital malformations (odds ratio [OR] 1." | 9.01 | The safety of oral fluconazole during the first trimester of pregnancy: a systematic review and meta-analysis. ( Jiang, CM; Jiang, HY; Zhang, X; Zhang, Z; Zhou, YY, 2019) |
| " Fluconazole (Diflucan((R)), Pfizer) is a triazole that has established an exceptional therapeutic record for candida infections including oropharyngeal and esophageal candidiasis, vulvovaginal candidiasis, candidemia and disseminated candidiasis." | 8.82 | Fluconazole for the treatment of candidiasis: 15 years experience. ( Cha, R; Sobel, JD, 2004) |
| "Any maternal exposure to fluconazole during pregnancy may increase risk of spontaneous abortion and doses higher than 150 mg during the first trimester may increase risk of cardiac septal closure anomalies." | 7.91 | Associations between low- and high-dose oral fluconazole and pregnancy outcomes: 3 nested case-control studies. ( Abrahamowicz, M; Bérard, A; Bernatsky, S; de Moura, CS; Gorgui, J; Sheehy, O; Zhao, JP, 2019) |
| "To study the association between oral fluconazole exposure during pregnancy and the risk of spontaneous abortion and stillbirth." | 7.83 | Association Between Use of Oral Fluconazole During Pregnancy and Risk of Spontaneous Abortion and Stillbirth. ( Hviid, A; Melbye, M; Mølgaard-Nielsen, D; Pasternak, B; Svanström, H, 2016) |
| " She took a 150-mg dose of fluconazole 2 weeks ago for the treatment of vaginal candidiasis and she is worried about the effect on her child and pregnancy." | 7.81 | Fluconazole exposure during pregnancy. ( Bozzo, P; Kaplan, YC; Koren, G, 2015) |
| " We compared the pregnancy outcomes of 226 women exposed to fluconazole with that of 452 women exposed to nonteratogenic agents, with use of logistic regression to control for potential confounders." | 7.69 | Prospective assessment of pregnancy outcomes after first-trimester exposure to fluconazole. ( Botto, LD; Caramelli, L; Finardi, A; Fusco, D; Mastroiacovo, P; Mazzone, T; Serafini, MA, 1996) |
| "In participants with recurrent vulvovaginal candidiasis, oteseconazole was safe and efficacious in the treatment and prevention of recurrent acute vulvovaginal candidiasis episodes and was noninferior to vulvovaginal candidiasis standard-of-care fluconazole in the treatment of the presenting acute vulvovaginal candidiasis infection." | 5.51 | Phase 3 study evaluating the safety and efficacy of oteseconazole in the treatment of recurrent vulvovaginal candidiasis and acute vulvovaginal candidiasis infections. ( Brand, SR; Curelop, S; Degenhardt, T; Flynt, A; Ghannoum, M; Martens, MG; Maximos, B; Person, K, 2022) |
| "Recurrence is also more common in pregnant women, and therapeutic responses are reduced." | 5.38 | Yeast vaginitis during pregnancy: susceptibility testing of 13 antifungal drugs and boric acid and the detection of four virulence factors. ( Aydin, M; Güzel, AB; Ilkit, M; Kalkanci, A; Khalil, II; Kuştimur, S, 2012) |
| "A prescription-event monitoring (PEM) study has confirmed that fluconazole, a bis-triazole oral antifungal drug, is a safe and effective treatment for vaginal candidiasis." | 5.29 | Safety of fluconazole in the treatment of vaginal candidiasis. A prescription-event monitoring study, with special reference to the outcome of pregnancy. ( Inman, W; Pearce, G; Wilton, L, 1994) |
| " Fluconazole during pregnancy may be associated with spontaneous abortion and craniofacial and heart defects." | 5.22 | Vulvovaginal Candidiasis: A Review of the Evidence for the 2021 Centers for Disease Control and Prevention of Sexually Transmitted Infections Treatment Guidelines. ( Brookhart, C; Lazenby, G; Nyirjesy, P; Schwebke, J; Sobel, JD, 2022) |
| "Oral fluconazole use during the first trimester of pregnancy was marginally associated with an increased risk of congenital malformations (odds ratio [OR] 1." | 5.01 | The safety of oral fluconazole during the first trimester of pregnancy: a systematic review and meta-analysis. ( Jiang, CM; Jiang, HY; Zhang, X; Zhang, Z; Zhou, YY, 2019) |
| " Because half of all pregnancies are unplanned and pregnant women have an increased risk of VVC recurrence, the likelihood of inadvertently being exposed to fluconazole in pregnancy is increased." | 4.91 | Exposure to fluconazole and risk of congenital malformations in the offspring: A systematic review and meta-analysis. ( Alsaad, AM; Kaplan, YC; Koren, G, 2015) |
| " Fluconazole (Diflucan((R)), Pfizer) is a triazole that has established an exceptional therapeutic record for candida infections including oropharyngeal and esophageal candidiasis, vulvovaginal candidiasis, candidemia and disseminated candidiasis." | 4.82 | Fluconazole for the treatment of candidiasis: 15 years experience. ( Cha, R; Sobel, JD, 2004) |
| "To examine the risk of congenital malformations associated with exposure to oral fluconazole at commonly used doses in the first trimester of pregnancy for the treatment of vulvovaginal candidiasis." | 3.96 | Oral fluconazole use in the first trimester and risk of congenital malformations: population based cohort study. ( Bateman, BT; Gray, KJ; Hernandez-Diaz, S; Huybrechts, KF; Mogun, H; Straub, L; Zhu, Y, 2020) |
| "Any maternal exposure to fluconazole during pregnancy may increase risk of spontaneous abortion and doses higher than 150 mg during the first trimester may increase risk of cardiac septal closure anomalies." | 3.91 | Associations between low- and high-dose oral fluconazole and pregnancy outcomes: 3 nested case-control studies. ( Abrahamowicz, M; Bérard, A; Bernatsky, S; de Moura, CS; Gorgui, J; Sheehy, O; Zhao, JP, 2019) |
| "To study the association between oral fluconazole exposure during pregnancy and the risk of spontaneous abortion and stillbirth." | 3.83 | Association Between Use of Oral Fluconazole During Pregnancy and Risk of Spontaneous Abortion and Stillbirth. ( Hviid, A; Melbye, M; Mølgaard-Nielsen, D; Pasternak, B; Svanström, H, 2016) |
| " She took a 150-mg dose of fluconazole 2 weeks ago for the treatment of vaginal candidiasis and she is worried about the effect on her child and pregnancy." | 3.81 | Fluconazole exposure during pregnancy. ( Bozzo, P; Kaplan, YC; Koren, G, 2015) |
| " It can be used as an alternative therapy for candidiasis, either alone or in combination with fluconazole." | 3.78 | Therapeutic use of a cationic antimicrobial peptide from the spider Acanthoscurria gomesiana in the control of experimental candidiasis. ( Belmonte, R; Borelli, P; Carvalho, DD; Daffre, S; Faintuch, B; Miranda, A; Muñoz, JE; Rossi, DC; Taborda, CP, 2012) |
| " We compared the pregnancy outcomes of 226 women exposed to fluconazole with that of 452 women exposed to nonteratogenic agents, with use of logistic regression to control for potential confounders." | 3.69 | Prospective assessment of pregnancy outcomes after first-trimester exposure to fluconazole. ( Botto, LD; Caramelli, L; Finardi, A; Fusco, D; Mastroiacovo, P; Mazzone, T; Serafini, MA, 1996) |
| "Vulvovaginal candidiasis affects approximately 75% of women in their lifetime." | 3.11 | Phase 2 Randomized Study of Oral Ibrexafungerp Versus Fluconazole in Vulvovaginal Candidiasis. ( Angulo, DA; Azie, NE; Harriott, IA; Nyirjesy, P; Schwebke, JR; Sobel, JD, 2022) |
| "Fluconazole is a well-established antifungal drug commonly utilized for acute and long-term RVVC treatment." | 3.01 | Interplay of the microbiome and antifungal therapy in recurrent vulvovaginal candidiasis (RVVC): A narrative review. ( Bradfield Strydom, M; Khan, S; Tiralongo, E; Walpola, RL; Ware, RS, 2023) |
| " In December 2022, Ibrexafungerp received FDA approval for once monthly dosing to decrease the incidence of RVVC." | 3.01 | Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis: Design, Development and Place in Therapy. ( Merjanian, L; Phillips, NA; Rocktashel, M, 2023) |
| "We evaluated the efficacy and safety of 4 dosing regimens of oral VT-1161 compared with placebo in women with recurrent vulvovaginal candidiasis, which was defined as at least 3 symptomatic episodes of acute vulvovaginal candidiasis within a 12-month period." | 2.87 | A phase 2, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of orally administered VT-1161 in the treatment of recurrent vulvovaginal candidiasis. ( Brand, SR; Degenhardt, TP; Nyirjesy, P; Person, K; Schotzinger, RJ; Sobel, JD; Tavakkol, A, 2018) |
| " The adverse events of clotrimazole were mainly local." | 2.82 | The efficacy and safety of clotrimazole vaginal tablet vs. oral fluconazole in treating severe vulvovaginal candidiasis. ( Fan, S; Guo, X; Li, T; Liang, Y; Liu, X; Zhou, X; Zhu, Y, 2016) |
| "Miconazole is a synthetic imidazole antifungal that has a broad spectrum of activity against Candida albicans and non-albicans Candida species." | 2.80 | Miconazole nitrate vaginal suppository 1,200 mg versus oral fluconazole 150 mg in treating severe vulvovaginal candidiasis. ( Fan, S; Liang, Y; Liu, X, 2015) |
| " Local irritation was the primary adverse event associated with terconazole, whereas systemic side effects were associated with fluconazole; however, these effects were minimal." | 2.80 | A randomized clinical trial of the efficacy and safety of terconazole vaginal suppository versus oral fluconazole for treating severe vulvovaginal candidiasis. ( Fan, S; Li, T; Liang, Y; Liu, X; Xu, H; Zhu, Y, 2015) |
| "For the treatment of vulvovaginal candidiasis, antifungal agents are used either as topical (vaginal tablets and cream) or oral formulations." | 2.80 | Efficacy and safety of a single oral 150 mg dose of fluconazole for the treatment of vulvovaginal candidiasis in Japan. ( Matsumizu, M; Mikamo, H; Nagashima, M; Nakazuru, Y; Okayama, A, 2015) |
| "The primary end points were bacterial vaginosis (BV), vaginal candidiasis, trichomoniasis vaginalis (hereafter, "trichomoniasis"), and colonization with Lactobacillus organisms." | 2.73 | Improvement of vaginal health for Kenyan women at risk for acquisition of human immunodeficiency virus type 1: results of a randomized trial. ( Baeten, JM; Chohan, V; Hassan, WM; Holmes, KK; Jaoko, W; Kiarie, J; Kurth, AE; Lavreys, L; Mandaliya, K; McClelland, RS; Ndinya-Achola, JO; Richardson, BA, 2008) |
| "Fluconazole is a bis-triazole agent used in the treatment of superficial and systemic fungal infections, with vaginal candidiasis being one of the commonest indications to fluconazole treatment." | 2.72 | Maternal use of fluconazole and congenital malformations in the progeny: A meta-analysis of the literature. ( Budani, MC; Di Marzio, M; Fensore, S; Tiboni, GM, 2021) |
| "Fluconazole was discontinued in one patient because of headache." | 2.71 | Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. ( Chu, TC; Danna, P; Edwards, L; Hooton, TM; Horowitz, B; Livengood, C; Martens, M; Panzer, H; Rompalo, A; Sobel, JD; Sperling, M; Von Thron, J; Wiesenfeld, HC, 2004) |
| "Butoconazole therapy was shown to have fewer reported adverse events, including drug-related adverse events, than fluconazole therapy." | 2.71 | An evaluation of butoconazole nitrate 2% site release vaginal cream (Gynazole-1) compared to fluconazole 150 mg tablets (Diflucan) in the time to relief of symptoms in patients with vulvovaginal candidiasis. ( Seidman, LS; Skokos, CK, 2005) |
| "Fluconazole therapy was well tolerated and free of serious adverse effects." | 2.70 | Treatment of complicated Candida vaginitis: comparison of single and sequential doses of fluconazole. ( Heine, MW; Hooton, T; Kapernick, PS; Nyirjesy, P; Panzer, H; Reed, BD; Sobel, JD; Soper, D; Willems, J; Wittes, H; Zervos, M, 2001) |
| "Fluconazole was associated with a 50% reduction in the odds of being colonized with C." | 2.69 | Evolution of vaginal Candida species recovered from human immunodeficiency virus-infected women receiving fluconazole prophylaxis: the emergence of Candida glabrata? Terry Beirn Community Programs for Clinical Research in AIDS (CPCRA). ( Holloway, W; Neaton, JD; Peng, G; Schuman, P; Sobel, JD; Steele-Moore, L; Vazquez, JA, 1999) |
| " Significant adverse effects were reported in less than one per cent of patients." | 2.67 | An open multicentre study of the efficacy and safety of a single dose of fluconazole 150 mg in the treatment of vaginal candidiasis in general practice. ( McKay, FF; Phillips, RJ; Watson, SA, 1990) |
| "Fluconazole is a new oral triazole antifungal with good activity against Candida spp." | 2.67 | Comparative study of fluconazole and clotrimazole in the treatment of vulvovaginal candidiasis. ( Christensen, S; Mummaw, N; Stein, GE, 1991) |
| "Vulvovaginal candidiasis is estimated to be the second most common cause of vaginitis after bacterial vaginosis." | 2.52 | Candidiasis (vulvovaginal). ( Martin Lopez, JE, 2015) |
| "Fluconazole was more effective than placebo in reducing symptomatic episodes of VVC, immediately after treatment (OR 0." | 2.49 | Weekly fluconazole therapy for recurrent vulvovaginal candidiasis: a systematic review and meta-analysis. ( Madeira, K; Medeiros, LR; Panatto, AP; Pires, PS; Rosa, MI; Silva, BR; Silva, FR; Silva, NC; Souza, SL, 2013) |
| "Vulvovaginal candidiasis is estimated to be the second most common cause of vaginitis after bacterial vaginosis." | 2.46 | Candidiasis (vulvovaginal). ( Spence, D, 2010) |
| "Fluconazole is an oral drug of choice for continuous treatment of vaginal yeast infection with the least toxicity." | 2.42 | [Vaginal candidiasis--treatment protocols using miconazole and fluconazole]. ( Mazneĭkova, V, 2003) |
| "Because many patients experience recurrences once prophylaxis is discontinued, long-term therapy may be warranted." | 2.41 | Treatment of recurrent vulvovaginal candidiasis. ( Ringdahl, EN, 2000) |
| "Fluconazole is a triazole antifungal agent that acts primarily by inhibiting sterol synthesis in the fungal cell membrane." | 2.39 | Oral fluconazole for vaginal candidiasis. ( Desai, PC; Johnson, BA, 1996) |
| "Fluconazole also has shown promise at diminishing VVC relapse or recurrence, possibly because of more complete vaginal and rectal eradication of Candida species." | 2.38 | Is there a role for fluconazole in the treatment of vulvovaginal candidiasis? ( Patel, HS; Peters, MD; Smith, CL, 1992) |
| "Vulvovaginal candidiasis is a fungal infection for which we search for alternatives for its treatment." | 1.91 | Fluconazole and propolis co-encapsulated in chitosan nanoparticles for the treatment of vulvovaginal candidiasis in a murine model. ( Alves, SF; Amaral, AC; Costa, AF; da Silva, JT; Dantas de Sousa, PH; de Menezes, LB; Pellegrini, F, 2023) |
| "Vulvovaginal candidiasis is an important cause of morbidity among women due to Candida species." | 1.72 | First detection of mutated ERG11 gene in vulvovaginal Candida albicans isolates at Ouagadougou/Burkina Faso. ( Belemgnegre, M; Dabire, AM; Djigma, FW; Dovo, EE; Kiendrebeogo, IT; Nadembega, CW; Obiri-Yeboah, D; Ouedraogo, P; Ouedraogo, RA; Simpore, J; Soubeiga, ST; Tovo, SF; Yonli, AT; Zohoncon, TM, 2022) |
| "We describe 11 cases of refractory vulvovaginal yeast infections (RVVYI) treated using oral voriconazole with or without concomitant topical agents." | 1.72 | Outcomes and experiences of using oral voriconazole with or without concomitant topical agents to treat refractory vulvovaginal yeast infections. ( Dean, G; Fearnley, N; Morris, GC; Soni, S; Sundaram, S; Wilson, JD, 2022) |
| "In the present study, we assessed the adjunct effect of vitamin D3 in combination with Fluconazole (FLZ) against Vulvovaginal Candidiasis (VVC) in mice." | 1.62 | Prophylactic and Therapeutic Role of Vitamin D3 in Combination with Fluconazole Against Vaginal Candidiasis in a Murine Model. ( Allemailem, KS, 2021) |
| "If left untreated, vulvovaginal candidiasis (VVC) can lead to chorioamnionitis with subsequent abortion, prematurity and congenital infection of the neonate." | 1.56 | Prevalence of vulvovaginal candidiasis among pregnant women in the Ho municipality, Ghana: species identification and antifungal susceptibility of Candida isolates. ( Afeke, I; Agede, CY; Asiamah, EA; Deku, JG; Dodoo, C; Kasu, ES; Korbuvi, J; Kwawu, GS; Louis, B; Mbroh, HK; Mensah, P; Opintan, JA; Osei, GY; Tampuori, J; Waikhom, SD, 2020) |
| " Data included long-term use of fluconazole therapy, treatment efficacy, and development of fluconazole resistance." | 1.56 | Prognosis and Long-Term Outcome of Women With Idiopathic Recurrent Vulvovaginal Candidiasis Caused by Candida albicans. ( Collins, LM; Moore, R; Sobel, JD, 2020) |
| "Vulvovaginal candidiasis is a global issue of concern due to its association with economic costs, sexually transmitted infections, and ascending genital tract infection." | 1.48 | Vulvovaginal candidiasis: species distribution of Candida and their antifungal susceptibility pattern. ( Abebaw, Y; Bitew, A, 2018) |
| "Chronic vulvovaginal candidiasis is usually responsive to therapy with oral antifungals." | 1.48 | Chronic vulvovaginal candidiasis in patients using a levonorgestrel-containing intrauterine device. ( Fischer, G; Nguyen, Y, 2018) |
| "We aimed to determine the rate of recurrence at a minimum of 6 months after completion of maintenance therapy." | 1.48 | Long-Term Outcomes of Women With Recurrent Vulvovaginal Candidiasis After a Course of Maintenance Antifungal Therapy. ( Crouss, T; Nyirjesy, P; Smith, K; Sobel, JD, 2018) |
| " Fluconazole is widely regarded as the antifungal drug of choice since its introduction in 1990 due to its high oral bioavailability, convenient dosing regimen and favourable safety profile." | 1.46 | Antifungal peptides: a potential new class of antifungals for treating vulvovaginal candidiasis caused by fluconazole-resistant Candida albicans. ( Barkham, T; Cheong, JW; Chia, CS; Hill, J; Lau, QY; Ng, FM; Ng, SM; Teo, JW; Yap, YY, 2017) |
| "Fluconazole treatment at a dose of 50-100 mg daily achieved a significant observable and improvement in the QoL of 96% of patients with CVVC within 12 weeks of treatment." | 1.46 | Quality of life in patients with chronic vulvovaginal candidiasis: A before and after study on the impact of oral fluconazole therapy. ( Fischer, G; Lee, A; Nguyen, Y, 2017) |
| "Recurrent vulvovaginal candidiasis is defined as having three to four episodes per year and causes substantial suffering." | 1.46 | Elevated nitric oxide in recurrent vulvovaginal candidiasis - association with clinical findings. ( Alvendal, C; Bohm-Starke, N; Brauner, A; Ehrström, S; Lundberg, JO, 2017) |
| "Quercetin (QCT) is a dietary flavonoid and has been demonstrated to be antifungal against C." | 1.43 | Quercetin Assists Fluconazole to Inhibit Biofilm Formations of Fluconazole-Resistant Candida Albicans in In Vitro and In Vivo Antifungal Managements of Vulvovaginal Candidiasis. ( Gao, M; Wang, H; Zhu, L, 2016) |
| "Boric acid was effective at obtaining MC in 32 (78%) of 41 patients with C." | 1.43 | Non-albicans Candida Vulvovaginitis: Treatment Experience at a Tertiary Care Vaginitis Center. ( Gracely, E; Nyirjesy, P; Powell, AM, 2016) |
| "Hymenal stenosis and fibrosis can develop in the absence of identifiable vulvar dermatoses." | 1.42 | Hymenal stenosis and fibrosis in two adult women. ( Bedell, S; Goldstein, AT; Tabbarah, A; Todd, S, 2015) |
| "Vulvovaginal candidiasis is the most common mycosis, however, the available information about antifungal susceptibilities of these yeasts is limited." | 1.42 | [Yeast species in vulvovaginitis candidosa]. ( Mihalik, N; Nemes-Nikodém, É; Ostorházi, E; Tamási, B, 2015) |
| "The purpose of this work was to determine the antimicrobial activity of fluoxetine, alone and combined with fluconazole, against 29 Candida strains isolated from patients with vulvovaginal candidiasis." | 1.40 | Anti-Candida activity of fluoxetine alone and combined with fluconazole: a synergistic action against fluconazole-resistant strains. ( Gaspar, CA; Martinez-de-Oliveira, J; Oliveira, AS; Palmeira-de-Oliveira, A; Palmeira-de-Oliveira, R, 2014) |
| "Recurrence is also more common in pregnant women, and therapeutic responses are reduced." | 1.38 | Yeast vaginitis during pregnancy: susceptibility testing of 13 antifungal drugs and boric acid and the detection of four virulence factors. ( Aydin, M; Güzel, AB; Ilkit, M; Kalkanci, A; Khalil, II; Kuştimur, S, 2012) |
| "Mostly, recurrences are caused by identical Candida strains suggesting C." | 1.37 | Recurrent vulvovaginal candidosis: focus on the vulva. ( Beikert, FC; Clad, A; Koeninger, A; Le, MT; Technau, K, 2011) |
| "Fluticasone was discontinued, and the patient's adrenal function normalized." | 1.37 | Rapid onset of iatrogenic adrenal insufficiency in a patient with cystic fibrosis-related liver disease treated with inhaled corticosteroids and a moderate CYP3A4 inhibitor. ( Britton, LJ; Gardner, J; Gutierrez, H; Hoover, WC; Jackson, T, 2011) |
| "Fenticonazole was assessed by European Committee on Antimicrobial Susceptibility Testing and CLSI microdilution methods for the first time, and the results showed excellent agreement (97%) and significant interclass correlation coefficient (P < 0." | 1.35 | Fenticonazole activity measured by the methods of the European Committee on Antimicrobial Susceptibility Testing and CLSI against 260 Candida vulvovaginitis isolates from two European regions and annotations on the prevalent genotypes. ( Alexopoulos, EC; Antonopoulou, S; Aoun, M; Baka, S; Grigoriou, O; Kalambokas, T; Kouskouni, E; Logothetis, E; Papadias, K; Velegraki, A; Zannos, A, 2009) |
| "Voriconazole was highly active (MIC50 0." | 1.35 | Trends in frequency and in vitro antifungal susceptibility patterns of Candida isolates from women attending the STD outpatients clinic of a tertiary care hospital in Northern Italy during the years 2002-2007. ( Asticcioli, S; Daturi, R; Matti, C; Nucleo, E; Pagani, L; Sacco, L; Zara, F, 2009) |
| "Vulvovaginal candidiasis is a condition that affects a great number of fertile women." | 1.34 | [Identification and susceptibility against fluconazole and albaconazole of 100 yeasts' strains isolated from vaginal discharge]. ( Arechavala, AI; Bianchi, MH; Negroni, R; Robles, AM; Santiso, G, 2007) |
| "The majority of women had a history of allergy (60%) and 10 of them (43%) had at least 1 positive result of a skin prick test to aeroallergens." | 1.33 | Successful treatment of refractory recurrent vaginal candidiasis with cetirizine plus fluconazole. ( Carvalho, EM; Carvalho, LP; Cruz, A; Lopes, AC; Neves, NA, 2005) |
| " However, one half of the women had either a clinically relevant increase of the INR greater than 4, or bleeding that required their dosage of warfarin to be decreased." | 1.33 | Single-dose fluconazole for vulvovaginal candidiasis: impact on prothrombin time in women taking warfarin. ( Turrentine, MA, 2006) |
| "Azoles are safe, effective agents to treat esophageal candidiasis." | 1.33 | Caspofungin in the treatment of azole-refractory esophageal candidiasis in kidney transplant recipients. ( Cappello, D; Di Mare, M; Fiamingo, P; Gagliano, M; Giuffrida, G; Macarone, M; Severino, V; Sorbello, M; Spataro, M; Veroux, M; Veroux, P; Vizcarra, D, 2006) |
| "Vulvovaginal candidiasis is a common mucosal infection caused by opportunistic yeasts of the Candida genus." | 1.32 | Fluconazole and itraconazole susceptibility of vaginal yeast isolates from Slovakia. ( Borovsky, M; Liptajova, D; Sojakova, M; Subik, J, 2004) |
| "Of the 22 women who experienced recurrence, the same strain was responsible for the initial and recurrent episode in 17 women." | 1.31 | An investigation into the pathogenesis of vulvo-vaginal candidosis. ( Ashbee, HR; Barton, RC; El-Din, SS; Evans, EG; Reynolds, MT, 2001) |
| "No recurrences were noted at the 6-week follow-up." | 1.30 | Single-dose systemic oral fluconazole for the treatment of vaginal candidiasis. ( Gibor, Y; Kaplan, B; Rabinerson, D, 1997) |
| " The overall success rate is 90%, with a mean dosage of 100-200 mg/d." | 1.30 | Therapeutic experience with fluconazole in the treatment of fungal infections in diabetic patients. ( Penk, A; Pittrow, L, 1999) |
| "Eight cases of severe mucosal candidiasis in patients with AIDS who were taking fluconazole at a dosage of 400-800 mg/d are described." | 1.29 | Clinically significant mucosal candidiasis resistant to fluconazole treatment in patients with AIDS. ( Fisher, A; Flanigan, TP; Newman, SL; Rinaldi, MG; Stein, M; Vigilante, K, 1994) |
| "A prescription-event monitoring (PEM) study has confirmed that fluconazole, a bis-triazole oral antifungal drug, is a safe and effective treatment for vaginal candidiasis." | 1.29 | Safety of fluconazole in the treatment of vaginal candidiasis. A prescription-event monitoring study, with special reference to the outcome of pregnancy. ( Inman, W; Pearce, G; Wilton, L, 1994) |
| "The use of preventive treatment for fungal infections is cautioned due to the possibility of resistance to treatment." | 1.29 | Fungal infection overview. ( , 1995) |
| "Fluconazole is a new oral absorbing triazolic antimycotic, inhibiting specifically the sterol synthesis of fungal membrane." | 1.28 | [The treatment of vaginal candidiasis with a single oral dose of fluconazole]. ( Karag'ozov, I; Katsarova, M; Zlatkov, V, 1991) |
| "Fluconazole was about four times less effective than SM-8668 against systemic candidiasis and was only slightly effective at doses of 80 and 25 mg/kg against systemic aspergilosis and cryptococcosis, respectively." | 1.28 | In vivo efficacy of SM-8668 (Sch 39304), a new oral triazole antifungal agent. ( Ichise, K; Nakajima, T; Okuda, T; Tanio, T, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (2.79) | 18.7374 |
| 1990's | 51 (17.77) | 18.2507 |
| 2000's | 76 (26.48) | 29.6817 |
| 2010's | 95 (33.10) | 24.3611 |
| 2020's | 57 (19.86) | 2.80 |
| Authors | Studies |
|---|---|
| Gygax, SE | 1 |
| Vermitsky, JP | 1 |
| Chadwick, SG | 1 |
| Self, MJ | 1 |
| Zimmerman, JA | 1 |
| Mordechai, E | 1 |
| Adelson, ME | 1 |
| Trama, JP | 1 |
| Antonopoulou, S | 1 |
| Aoun, M | 1 |
| Alexopoulos, EC | 1 |
| Baka, S | 1 |
| Logothetis, E | 1 |
| Kalambokas, T | 1 |
| Zannos, A | 1 |
| Papadias, K | 1 |
| Grigoriou, O | 1 |
| Kouskouni, E | 1 |
| Velegraki, A | 1 |
| Ge, SH | 1 |
| Wan, Z | 1 |
| Li, J | 4 |
| Xu, J | 2 |
| Li, RY | 1 |
| Bai, FY | 1 |
| Nyirjesy, P | 12 |
| Schwebke, JR | 1 |
| Angulo, DA | 1 |
| Harriott, IA | 1 |
| Azie, NE | 1 |
| Sobel, JD | 26 |
| Ma, J | 1 |
| Yang, YC | 1 |
| Su, LQ | 1 |
| Qin, DM | 1 |
| Yuan, K | 1 |
| Zhang, Y | 1 |
| Wang, RR | 1 |
| Hong, N | 1 |
| Lei, Y | 1 |
| Chen, H | 2 |
| Chen, X | 1 |
| Tsui, KM | 1 |
| Hu, D | 1 |
| Liao, W | 1 |
| Yan, L | 1 |
| Zhang, H | 3 |
| Zhao, R | 1 |
| Wu, G | 1 |
| Yu, N | 1 |
| Deng, S | 1 |
| Brookhart, C | 1 |
| Lazenby, G | 1 |
| Schwebke, J | 1 |
| Salama, OE | 1 |
| Gerstein, AC | 1 |
| Barnes, KN | 1 |
| Yancey, AM | 1 |
| Forinash, AB | 1 |
| Intra, J | 1 |
| Sala, MR | 1 |
| Brambilla, P | 1 |
| Carcione, D | 1 |
| Leoni, V | 1 |
| Akins, R | 1 |
| de Souza, ANV | 1 |
| Faria, MGI | 1 |
| da Rocha, CE | 1 |
| Philippsen, GS | 1 |
| Silva, GCC | 1 |
| da Silva, GR | 1 |
| Inumaro, RS | 1 |
| Gonçalves, JE | 1 |
| Gazim, ZC | 1 |
| Wietzikoski, S | 1 |
| Lívero, FADR | 1 |
| Seixas, FAV | 1 |
| Wietzikoski Lovato, EC | 1 |
| Martens, MG | 1 |
| Maximos, B | 1 |
| Degenhardt, T | 1 |
| Person, K | 2 |
| Curelop, S | 1 |
| Ghannoum, M | 1 |
| Flynt, A | 1 |
| Brand, SR | 3 |
| Esfahani, A | 1 |
| Omran, AN | 1 |
| Salehi, Z | 1 |
| Shams-Ghahfarokhi, M | 1 |
| Ghane, M | 1 |
| Eybpoosh, S | 1 |
| Razzaghi-Abyaneh, M | 1 |
| Dovo, EE | 1 |
| Zohoncon, TM | 1 |
| Tovo, SF | 1 |
| Soubeiga, ST | 1 |
| Kiendrebeogo, IT | 1 |
| Yonli, AT | 1 |
| Ouedraogo, RA | 1 |
| Dabire, AM | 1 |
| Djigma, FW | 1 |
| Nadembega, CW | 1 |
| Belemgnegre, M | 1 |
| Ouedraogo, P | 1 |
| Obiri-Yeboah, D | 1 |
| Simpore, J | 1 |
| Sucher, AJ | 1 |
| Thai, A | 1 |
| Tran, C | 1 |
| Mantena, N | 1 |
| Noronha, A | 1 |
| Chahine, EB | 1 |
| Bouglita, W | 1 |
| Rabhi, S | 1 |
| Raich, N | 1 |
| Bouabid, C | 1 |
| Belghith, C | 1 |
| Slimani, O | 1 |
| Hkimi, C | 1 |
| Ghedira, K | 1 |
| Karess, RE | 1 |
| Guizani-Tabbane, L | 1 |
| Attia, L | 1 |
| Rabhi, I | 1 |
| Donders, G | 4 |
| Sziller, IO | 1 |
| Paavonen, J | 1 |
| Hay, P | 1 |
| de Seta, F | 1 |
| Bohbot, JM | 1 |
| Kotarski, J | 1 |
| Vives, JA | 1 |
| Szabo, B | 1 |
| Cepuliené, R | 1 |
| Mendling, W | 2 |
| Khaksar Baniasadi, A | 1 |
| Ayatollahi Mosavi, SA | 1 |
| Sharifi, I | 1 |
| Bamorovat, M | 1 |
| Salari, S | 1 |
| Ahmadi, A | 1 |
| Amanizadeh, A | 1 |
| Agha Kuchak Afshari, S | 1 |
| Mollazadeh-Narestan, Z | 1 |
| Yavarikia, P | 1 |
| Homayouni-Rad, A | 1 |
| Samadi Kafil, H | 1 |
| Mohammad-Alizadeh-Charandabi, S | 1 |
| Gholizadeh, P | 1 |
| Mirghafourvand, M | 1 |
| Pang, Q | 4 |
| Liu, W | 5 |
| Cui, F | 4 |
| Kan, S | 4 |
| Li, X | 4 |
| Morris, GC | 1 |
| Dean, G | 1 |
| Soni, S | 1 |
| Sundaram, S | 1 |
| Fearnley, N | 1 |
| Wilson, JD | 1 |
| Song, N | 3 |
| Mei, H | 4 |
| Zheng, H | 3 |
| Li, D | 7 |
| Lv, G | 4 |
| An, R | 3 |
| Li, P | 3 |
| Xiong, Z | 3 |
| Fan, S | 8 |
| Zhang, M | 4 |
| Chen, Y | 3 |
| Qiao, Q | 3 |
| Liang, X | 4 |
| Cui, M | 3 |
| Liao, Q | 3 |
| Czechowicz, P | 3 |
| Nowicka, J | 3 |
| Neubauer, D | 3 |
| Chodaczek, G | 3 |
| Krzyżek, P | 3 |
| Gościniak, G | 3 |
| Carvalho, GC | 2 |
| Marena, GD | 2 |
| Leonardi, GR | 2 |
| Sábio, RM | 2 |
| Corrêa, I | 2 |
| Chorilli, M | 2 |
| Bauab, TM | 2 |
| Odame, F | 1 |
| Neglo, D | 1 |
| Sedohia, D | 1 |
| Arthur, R | 1 |
| Agrawal, P | 1 |
| Yazdy, G | 1 |
| Ghanem, KG | 1 |
| Handa, VL | 1 |
| Schumacher, CM | 1 |
| Zhang, SX | 1 |
| Tuddenham, S | 1 |
| Phillips, NA | 1 |
| Rocktashel, M | 1 |
| Merjanian, L | 1 |
| Sebastian, S | 1 |
| Boikov, DA | 1 |
| File, B | 1 |
| Sobel, R | 2 |
| Becker, M | 1 |
| Hu, KF | 1 |
| Mo, L | 1 |
| Xia, D | 2 |
| Shi, GX | 1 |
| Wu, DQ | 1 |
| Wang, TM | 1 |
| Shao, J | 2 |
| Wang, CZ | 1 |
| Nikoomanesh, F | 1 |
| Falahatinejad, M | 1 |
| Černáková, L | 1 |
| Dos Santos, ALS | 1 |
| Mohammadi, SR | 1 |
| Rafiee, M | 1 |
| Rodrigues, CF | 1 |
| Roudbary, M | 1 |
| Lietz, A | 1 |
| Eckel, F | 1 |
| Kiss, H | 1 |
| Noe-Letschnig, M | 1 |
| Farr, A | 1 |
| Bradfield Strydom, M | 1 |
| Khan, S | 1 |
| Walpola, RL | 1 |
| Ware, RS | 1 |
| Tiralongo, E | 1 |
| van Riel, SJJM | 1 |
| Lardenoije, CMJG | 1 |
| Wassen, MMLH | 1 |
| van Kuijk, SMJ | 1 |
| Cremers, NAJ | 1 |
| Hellier, SD | 1 |
| Wrynn, AF | 1 |
| da Silva, JT | 1 |
| Dantas de Sousa, PH | 1 |
| Costa, AF | 1 |
| de Menezes, LB | 1 |
| Alves, SF | 1 |
| Pellegrini, F | 1 |
| Amaral, AC | 1 |
| Pacuła-Miszewska, AJ | 1 |
| Obieziurska-Fabisiak, M | 1 |
| Vartak, R | 2 |
| Mao, G | 1 |
| Patel, K | 2 |
| Fedosova, NU | 1 |
| Ścianowski, J | 1 |
| Billack, B | 2 |
| Zhang, Z | 2 |
| Zhang, X | 1 |
| Zhou, YY | 1 |
| Jiang, CM | 1 |
| Jiang, HY | 1 |
| Woodburn, KW | 1 |
| Clemens, LE | 1 |
| Jaynes, J | 1 |
| Joubert, LM | 1 |
| Botha, A | 1 |
| Nazik, H | 1 |
| Stevens, DA | 1 |
| Feng, W | 1 |
| Yang, J | 1 |
| Ji, Y | 1 |
| Xi, Z | 1 |
| Yang, L | 1 |
| Zhu, X | 1 |
| Ma, Y | 1 |
| Collins, LM | 1 |
| Moore, R | 1 |
| Ghaddar, N | 1 |
| Anastasiadis, E | 1 |
| Halimeh, R | 1 |
| Ghaddar, A | 1 |
| Dhar, R | 1 |
| AlFouzan, W | 1 |
| Yusef, H | 1 |
| El Chaar, M | 1 |
| Gonçalves, B | 1 |
| Bernardo, R | 1 |
| Wang, C | 3 |
| Schröder, MS | 1 |
| Pedro, NA | 1 |
| Butler, G | 1 |
| Azeredo, J | 1 |
| Henriques, M | 1 |
| Pereira Mira, N | 1 |
| Silva, S | 1 |
| Donders, GG | 2 |
| Grinceviciene, S | 5 |
| Ruban, K | 4 |
| Bellen, G | 8 |
| Bai, HH | 2 |
| Wang, FJ | 2 |
| Li, T | 3 |
| Zong, XN | 1 |
| Shang, CG | 1 |
| Liu, ZH | 2 |
| Akdağ, D | 1 |
| Pullukçu, H | 1 |
| Yamazhan, T | 1 |
| Metin, DY | 1 |
| Sipahi, OR | 1 |
| Ener, B | 1 |
| Işıkgöz Taşbakan, M | 1 |
| Waikhom, SD | 1 |
| Afeke, I | 1 |
| Kwawu, GS | 1 |
| Mbroh, HK | 1 |
| Osei, GY | 1 |
| Louis, B | 1 |
| Deku, JG | 1 |
| Kasu, ES | 1 |
| Mensah, P | 1 |
| Agede, CY | 1 |
| Dodoo, C | 1 |
| Asiamah, EA | 1 |
| Tampuori, J | 1 |
| Korbuvi, J | 1 |
| Opintan, JA | 1 |
| Zhu, Y | 4 |
| Bateman, BT | 1 |
| Gray, KJ | 1 |
| Hernandez-Diaz, S | 1 |
| Mogun, H | 1 |
| Straub, L | 1 |
| Huybrechts, KF | 1 |
| Cordeiro, RA | 1 |
| de Andrade, ARC | 1 |
| Portela, FVM | 1 |
| Pereira, LMG | 1 |
| Moura, SGB | 1 |
| Sampaio, MD | 1 |
| Pereira, EMA | 1 |
| de Melo Guedes, GM | 1 |
| Bandeira, SP | 1 |
| de Lima-Neto, RG | 1 |
| Melo, VMM | 1 |
| Brilhante, RSN | 1 |
| Castelo-Branco, DSCM | 1 |
| Rocha, MFG | 1 |
| Sidrim, JJC | 1 |
| Ghannoum, MA | 1 |
| Schotzinger, RJ | 3 |
| Degenhardt, TP | 2 |
| Alvendal, C | 2 |
| Mohanty, S | 1 |
| Bohm-Starke, N | 2 |
| Brauner, A | 2 |
| Tan, KL | 1 |
| Bisconti, I | 1 |
| Leck, C | 1 |
| Billahalli, T | 1 |
| Barnett, S | 1 |
| Rajakulasingam, K | 1 |
| Watts, TJ | 1 |
| Budani, MC | 1 |
| Fensore, S | 1 |
| Di Marzio, M | 1 |
| Tiboni, GM | 1 |
| Allemailem, KS | 1 |
| Bender, RA | 1 |
| Çalışkan, Ş | 1 |
| Önal, B | 1 |
| Aslancan, R | 1 |
| Çalışkan, E | 1 |
| Borroto-Esoda, K | 1 |
| Azie, N | 1 |
| Angulo, D | 1 |
| Marin, B | 1 |
| Vauzelle, C | 1 |
| Coulm, B | 1 |
| Beghin, D | 1 |
| Latour, M | 1 |
| Tubach, F | 1 |
| Dechartres, A | 1 |
| Elefant, E | 1 |
| Mohammadi, F | 1 |
| Hemmat, N | 1 |
| Bajalan, Z | 1 |
| Javadi, A | 1 |
| Menon, S | 1 |
| Sherry, L | 1 |
| Kean, R | 1 |
| McKloud, E | 1 |
| O'Donnell, LE | 1 |
| Metcalfe, R | 1 |
| Jones, BL | 1 |
| Ramage, G | 1 |
| Zida, A | 1 |
| Yacouba, A | 1 |
| Bamba, S | 1 |
| Sangare, I | 1 |
| Sawadogo, M | 1 |
| Guiguemde, T | 1 |
| Kone, S | 1 |
| Traore, LK | 1 |
| Ouedraogo-Traore, R | 1 |
| Guiguemde, RT | 1 |
| Tasneem, U | 1 |
| Siddiqui, MT | 1 |
| Faryal, R | 1 |
| Shah, AA | 1 |
| Xie, HY | 1 |
| Feng, D | 1 |
| Wei, DM | 1 |
| Mei, L | 1 |
| Wang, X | 1 |
| Fang, F | 1 |
| Takalkar, D | 1 |
| Desai, N | 1 |
| Donders, GGG | 3 |
| Jaeger, M | 1 |
| Ten Oever, J | 1 |
| Netea, MG | 1 |
| Spitzer, M | 1 |
| Wiederhold, NP | 1 |
| Tavakkol, A | 1 |
| Zaidi, KU | 1 |
| Shah, F | 1 |
| Parmar, R | 1 |
| Thawani, V | 1 |
| Hacioglu, M | 1 |
| Guzel, CB | 1 |
| Savage, PB | 1 |
| Tan, ASB | 1 |
| Bitew, A | 1 |
| Abebaw, Y | 1 |
| Brandão, LDS | 1 |
| Boniek, D | 1 |
| Resende Stoianoff, MA | 1 |
| da Mata, FMR | 1 |
| de Azevedo, PRM | 1 |
| Fernandes, JV | 1 |
| Andrade, VS | 1 |
| Crouss, T | 1 |
| Smith, K | 1 |
| Esposito, E | 1 |
| Campolo, M | 1 |
| Casili, G | 1 |
| Lanza, M | 1 |
| Filippone, A | 1 |
| Peritore, AF | 1 |
| Cuzzocrea, S | 1 |
| Bérard, A | 1 |
| Sheehy, O | 1 |
| Zhao, JP | 1 |
| Gorgui, J | 1 |
| Bernatsky, S | 1 |
| de Moura, CS | 1 |
| Abrahamowicz, M | 1 |
| Moldenhauer, I | 1 |
| Pliquett, RU | 1 |
| Kreft, B | 1 |
| Sunderkötter, C | 1 |
| Alessio, C | 1 |
| Jandourek, A | 1 |
| Lee, JD | 1 |
| Sandison, T | 1 |
| Genovese, C | 1 |
| Cianci, A | 1 |
| Corsello, S | 1 |
| Ettore, G | 1 |
| Mattana, P | 1 |
| Tempera, G | 1 |
| Lírio, J | 1 |
| Giraldo, PC | 1 |
| Amaral, RL | 1 |
| Sarmento, ACA | 1 |
| Costa, APF | 1 |
| Gonçalves, AK | 1 |
| Sharma, C | 1 |
| Wankhede, S | 1 |
| Muralidhar, S | 1 |
| Prakash, A | 1 |
| Singh, PK | 1 |
| Kathuria, S | 1 |
| Kumar, DA | 1 |
| Khan, N | 1 |
| Randhawa, HS | 1 |
| Meis, JF | 1 |
| Chowdhary, A | 1 |
| Guo, H | 1 |
| Zhang, XL | 1 |
| Gao, LQ | 1 |
| Li, SX | 1 |
| Song, YJ | 1 |
| Akhtar, S | 1 |
| Masood, S | 1 |
| Tabassum, S | 1 |
| Rizvi, DA | 1 |
| Atabek, ME | 1 |
| Akyürek, N | 1 |
| Eklioglu, BS | 1 |
| D'Antuono, A | 2 |
| Bellavista, S | 2 |
| Gaspari, V | 1 |
| Filippini, A | 1 |
| Patrizi, A | 2 |
| Gunther, LS | 1 |
| Martins, HP | 2 |
| Gimenes, F | 1 |
| Abreu, AL | 1 |
| Consolaro, ME | 3 |
| Svidzinski, TI | 3 |
| Oliveira, AS | 1 |
| Gaspar, CA | 1 |
| Palmeira-de-Oliveira, R | 2 |
| Martinez-de-Oliveira, J | 2 |
| Palmeira-de-Oliveira, A | 2 |
| Mochache, V | 1 |
| McClelland, RS | 2 |
| Balkus, JE | 1 |
| Zhang, JY | 1 |
| Liu, JH | 1 |
| Liu, FD | 1 |
| Xia, YH | 1 |
| Wang, J | 1 |
| Liu, X | 6 |
| Zhang, ZQ | 1 |
| Zhu, N | 1 |
| Ying, Y | 1 |
| Huang, XT | 1 |
| Shan, Y | 1 |
| Kovachev, SM | 1 |
| Vatcheva-Dobrevska, RS | 1 |
| Wu, C | 1 |
| Xu, L | 1 |
| Nemes-Nikodém, É | 1 |
| Tamási, B | 1 |
| Mihalik, N | 1 |
| Ostorházi, E | 1 |
| Liang, Y | 3 |
| Alsaad, AM | 1 |
| Kaplan, YC | 2 |
| Koren, G | 2 |
| Dovnik, A | 1 |
| Golle, A | 1 |
| Novak, D | 1 |
| Arko, D | 1 |
| Takač, I | 1 |
| Goldstein, AT | 1 |
| Todd, S | 1 |
| Bedell, S | 1 |
| Tabbarah, A | 1 |
| Martin Lopez, JE | 1 |
| Xu, H | 1 |
| Kumar, D | 1 |
| Banerjee, T | 1 |
| Pratap, CB | 1 |
| Tilak, R | 1 |
| Mikamo, H | 1 |
| Matsumizu, M | 1 |
| Nakazuru, Y | 1 |
| Okayama, A | 1 |
| Nagashima, M | 1 |
| Powell, AM | 1 |
| Gracely, E | 1 |
| Garvey, EP | 1 |
| Hoekstra, WJ | 1 |
| Lilly, EA | 1 |
| Fidel, PL | 1 |
| Pendharkar, S | 1 |
| Brandsborg, E | 1 |
| Hammarström, L | 1 |
| Marcotte, H | 1 |
| Larsson, PG | 1 |
| Wang, L | 1 |
| Shen, Y | 1 |
| Zeng, R | 1 |
| Zhan, P | 1 |
| Bozzo, P | 1 |
| Ebrahimy, F | 1 |
| Dolatian, M | 1 |
| Moatar, F | 1 |
| Majd, HA | 1 |
| Mølgaard-Nielsen, D | 1 |
| Svanström, H | 1 |
| Melbye, M | 1 |
| Hviid, A | 1 |
| Pasternak, B | 1 |
| Khameneie, KM | 1 |
| Arianpour, N | 1 |
| Roozegar, R | 1 |
| Aklamli, M | 1 |
| Amiri, MM | 1 |
| Shi, G | 1 |
| Xu, Z | 1 |
| Wu, D | 1 |
| Wang, T | 1 |
| Zhou, X | 1 |
| Guo, X | 1 |
| Diaz, MC | 2 |
| Camponovo, R | 1 |
| Araya, I | 1 |
| Cerda, A | 1 |
| Santander, MP | 1 |
| Carrillo-Muñoz, AJ | 1 |
| Nguyen, Y | 3 |
| Lee, A | 2 |
| Fischer, G | 3 |
| Zhang, D | 1 |
| Wu, WX | 1 |
| Dong, HY | 1 |
| Davar, R | 1 |
| Nokhostin, F | 1 |
| Eftekhar, M | 1 |
| Sekhavat, L | 2 |
| Bashiri Zadeh, M | 1 |
| Shamsi, F | 1 |
| Briglio, J | 1 |
| Boatto, HF | 1 |
| Cavalcanti, SD | 1 |
| Del Negro, GM | 1 |
| Girão, MJ | 1 |
| Francisco, EC | 1 |
| Ishida, K | 1 |
| Gompertz, OF | 1 |
| Tapia, CV | 1 |
| Hermosilla, G | 1 |
| Fortes, P | 1 |
| Alburquenque, C | 1 |
| Bucarey, S | 1 |
| Salinas, H | 1 |
| Rodas, PI | 1 |
| Magne, F | 1 |
| Gao, M | 1 |
| Wang, H | 1 |
| Zhu, L | 1 |
| Ehrström, S | 1 |
| Lundberg, JO | 1 |
| Ng, SM | 1 |
| Yap, YY | 1 |
| Cheong, JW | 1 |
| Ng, FM | 1 |
| Lau, QY | 1 |
| Barkham, T | 1 |
| Teo, JW | 1 |
| Hill, J | 1 |
| Chia, CS | 1 |
| Sun, MG | 1 |
| Huang, Y | 1 |
| Xu, YH | 1 |
| Cao, YX | 1 |
| Babula, O | 1 |
| Linhares, IM | 1 |
| Witkin, SS | 1 |
| Bachhav, YG | 1 |
| Patravale, VB | 1 |
| Pavlova, E | 1 |
| Ivanov, S | 2 |
| Batashki, I | 1 |
| Byttebier, G | 1 |
| Verguts, L | 2 |
| Hinoul, P | 2 |
| Walckiers, R | 1 |
| Stalpaert, M | 1 |
| Vereecken, A | 1 |
| Van Eldere, J | 1 |
| Ono, F | 1 |
| Yasumoto, S | 1 |
| Martinez, RC | 1 |
| Franceschini, SA | 1 |
| Patta, MC | 1 |
| Quintana, SM | 1 |
| Candido, RC | 1 |
| Ferreira, JC | 1 |
| De Martinis, EC | 1 |
| Reid, G | 1 |
| Pikuza, VV | 1 |
| Chilova, RA | 1 |
| Ishchenko, AI | 1 |
| Shahid, Z | 1 |
| Tietz, HJ | 2 |
| Asticcioli, S | 1 |
| Sacco, L | 1 |
| Daturi, R | 1 |
| Matti, C | 1 |
| Nucleo, E | 1 |
| Zara, F | 1 |
| Pagani, L | 1 |
| Auler, ME | 1 |
| Morreira, D | 1 |
| Rodrigues, FF | 1 |
| Abr Ao, MS | 1 |
| Margarido, PF | 1 |
| Matsumoto, FE | 1 |
| Silva, EG | 1 |
| Silva, BC | 1 |
| Schneider, RP | 1 |
| Paula, CR | 3 |
| Kovachev, S | 2 |
| Nacheva, A | 2 |
| Vacheva-Dobrevska, R | 1 |
| Vasilev, N | 2 |
| Fan, SR | 1 |
| Liu, XP | 1 |
| Ausma, J | 1 |
| Vaneldere, J | 1 |
| Borgers, M | 1 |
| Janssens, D | 1 |
| Lattif, AA | 2 |
| Mukhopadhyay, G | 1 |
| Banerjee, U | 4 |
| Goswami, R | 4 |
| Prasad, R | 1 |
| Damke, E | 1 |
| Tsuzuki, JK | 1 |
| Cortez, DA | 1 |
| Ferreira, IC | 1 |
| Bertoni, TA | 1 |
| Batista, MR | 1 |
| Donati, L | 1 |
| Beikert, FC | 1 |
| Le, MT | 1 |
| Koeninger, A | 1 |
| Technau, K | 1 |
| Clad, A | 1 |
| Shokri, H | 1 |
| Khosravi, AR | 1 |
| Yalfani, R | 1 |
| Davis, JD | 1 |
| Harper, AL | 1 |
| Hoover, WC | 1 |
| Britton, LJ | 1 |
| Gardner, J | 1 |
| Jackson, T | 1 |
| Gutierrez, H | 1 |
| Spence, D | 4 |
| Ray, A | 1 |
| Ray, S | 1 |
| George, AT | 1 |
| Swaminathan, N | 1 |
| Baldi, E | 1 |
| Banzola, N | 1 |
| Zauli, S | 1 |
| da Silva, MC | 1 |
| Paiva, LC | 1 |
| Tabatabaii, A | 1 |
| Tezerjani, FZ | 1 |
| Kalkanci, A | 1 |
| Güzel, AB | 1 |
| Khalil, II | 1 |
| Aydin, M | 1 |
| Ilkit, M | 1 |
| Kuştimur, S | 1 |
| Rossi, DC | 1 |
| Muñoz, JE | 1 |
| Carvalho, DD | 1 |
| Belmonte, R | 1 |
| Faintuch, B | 1 |
| Borelli, P | 1 |
| Miranda, A | 1 |
| Taborda, CP | 1 |
| Daffre, S | 1 |
| Murina, F | 1 |
| Graziottin, A | 1 |
| Felice, R | 1 |
| Di Francesco, S | 1 |
| Mantegazza, V | 1 |
| Gomez-Moyano, E | 1 |
| Cid Lama, A | 1 |
| Fernández Ballesteros, MD | 1 |
| Lova Navarro, M | 1 |
| Vera Casaño, A | 1 |
| Crespo Erchiga, V | 1 |
| Gomes-de-Elvas, AR | 1 |
| Gaspar, C | 1 |
| Gouveia, P | 1 |
| Pina-Vaz, C | 1 |
| Rodrigues, AG | 1 |
| Bavbek, S | 1 |
| Yilmaz, İ | 1 |
| Sözener, ZÇ | 1 |
| Marchaim, D | 1 |
| Lemanek, L | 1 |
| Bheemreddy, S | 1 |
| Kaye, KS | 1 |
| Rosa, MI | 1 |
| Silva, BR | 1 |
| Pires, PS | 1 |
| Silva, FR | 2 |
| Silva, NC | 1 |
| Souza, SL | 1 |
| Madeira, K | 1 |
| Panatto, AP | 1 |
| Medeiros, LR | 1 |
| Dorrell, L | 1 |
| Edwards, A | 1 |
| Bauters, TG | 1 |
| Dhont, MA | 2 |
| Temmerman, MI | 1 |
| Nelis, HJ | 2 |
| Ressel, GW | 1 |
| Ergin, A | 1 |
| Arikan, S | 1 |
| Zervos, M | 2 |
| Reed, BD | 2 |
| Hooton, T | 2 |
| Soper, D | 2 |
| Heine, MW | 2 |
| Willems, J | 2 |
| Panzer, H | 3 |
| De Punzio, C | 1 |
| Garutti, P | 1 |
| Mollica, G | 1 |
| Nappi, C | 1 |
| Piccoli, R | 1 |
| Genazzani, AR | 1 |
| Mondello, F | 2 |
| De Bernardis, F | 3 |
| Girolamo, A | 2 |
| Salvatore, G | 2 |
| Cassone, A | 3 |
| Stenberg-Nilsen, H | 1 |
| Mazneĭkova, V | 1 |
| Costa, M | 1 |
| Passos, XS | 1 |
| Miranda, AT | 1 |
| de Araújo, RS | 1 |
| Silva, Mdo R | 1 |
| Krauss, C | 1 |
| Fladung, B | 1 |
| Sojakova, M | 1 |
| Liptajova, D | 1 |
| Borovsky, M | 1 |
| Subik, J | 2 |
| Vacheva-Dobrevski, R | 1 |
| Stoev, S | 1 |
| Kairon, R | 1 |
| Godbole, S | 1 |
| Kulkarni, S | 1 |
| Ghate, M | 1 |
| Sane, S | 1 |
| Mehendale, S | 1 |
| Risbud, A | 1 |
| Shrotri, A | 1 |
| Bharucha, K | 1 |
| Eschenbach, DA | 1 |
| Wiesenfeld, HC | 1 |
| Martens, M | 1 |
| Danna, P | 1 |
| Hooton, TM | 1 |
| Rompalo, A | 1 |
| Sperling, M | 1 |
| Livengood, C | 1 |
| Horowitz, B | 1 |
| Von Thron, J | 1 |
| Edwards, L | 1 |
| Chu, TC | 1 |
| Marrazzo, J | 1 |
| McCaig, LF | 1 |
| McNeil, MM | 1 |
| Cha, R | 1 |
| Marinov, B | 1 |
| Petkova, S | 1 |
| Konovalova, M | 1 |
| Kolarov, G | 2 |
| Bern, VH | 1 |
| Kuebrich, CT | 1 |
| Retzer, DR | 1 |
| Buscemi, L | 1 |
| Arechavala, A | 1 |
| Negroni, R | 2 |
| Goswami, D | 3 |
| Dadhwal, V | 3 |
| Miglani, S | 1 |
| Kochupillai, N | 3 |
| Ventolini, G | 2 |
| Baggish, MS | 2 |
| Borisov, I | 1 |
| Bobcheva, S | 1 |
| Ivanova, A | 1 |
| Pekhlivanov, B | 1 |
| Amaliev, I | 1 |
| Ivancheva, Kh | 1 |
| Zisova, L | 1 |
| Neves, NA | 1 |
| Carvalho, LP | 1 |
| Lopes, AC | 1 |
| Cruz, A | 1 |
| Carvalho, EM | 1 |
| De Vos, MM | 1 |
| Cuenca-Estrella, M | 1 |
| Boekhout, T | 1 |
| Theelen, B | 1 |
| Matthijs, N | 1 |
| Bauters, T | 1 |
| Nailis, H | 1 |
| Rodriguez-Tudela, JL | 1 |
| Seidman, LS | 1 |
| Skokos, CK | 1 |
| Villagrana-Zesati, R | 1 |
| Reyna-Figueroa, J | 1 |
| Ortiz-Ibarra, J | 1 |
| Ribeiro, MA | 1 |
| John, R | 1 |
| Perfect, JR | 1 |
| Cox, GM | 1 |
| Turrentine, MA | 1 |
| Ozcan, SK | 1 |
| Budak, F | 1 |
| Yucesoy, G | 1 |
| Susever, S | 1 |
| Willke, A | 1 |
| Lewerenz, V | 1 |
| Bruch-Gerharz, D | 1 |
| Ruzicka, T | 1 |
| Kruse, R | 1 |
| Cernicka, J | 1 |
| Veroux, M | 1 |
| Macarone, M | 1 |
| Fiamingo, P | 1 |
| Cappello, D | 1 |
| Gagliano, M | 1 |
| Di Mare, M | 1 |
| Vizcarra, D | 1 |
| Spataro, M | 1 |
| Giuffrida, G | 1 |
| Sorbello, M | 1 |
| Severino, V | 1 |
| Veroux, P | 1 |
| Walsh, PM | 1 |
| Corić, M | 1 |
| Barisić, D | 1 |
| Lovrić, H | 1 |
| Ray, D | 2 |
| Mandal, P | 1 |
| Sreenivas, V | 1 |
| González, GM | 1 |
| Robledo, E | 1 |
| Saldívar, D | 1 |
| González, G | 1 |
| Bosques, F | 1 |
| Garza, E | 1 |
| Chen, S | 1 |
| Li, S | 1 |
| Liu, Z | 1 |
| Wu, Y | 1 |
| Tu, Y | 1 |
| Pitsouni, E | 1 |
| Iavazzo, C | 1 |
| Falagas, ME | 1 |
| Arechavala, AI | 1 |
| Bianchi, MH | 1 |
| Robles, AM | 1 |
| Santiso, G | 1 |
| Angiolella, L | 1 |
| Stringaro, AR | 1 |
| Posteraro, B | 1 |
| Bonito, M | 1 |
| Toccacieli, L | 1 |
| Torosantucci, A | 1 |
| Colone, M | 1 |
| Sanguinetti, M | 1 |
| Palamara, AT | 1 |
| Savini, V | 1 |
| Catavitello, C | 1 |
| Manna, A | 1 |
| Talia, M | 1 |
| Febbo, F | 1 |
| Balbinot, A | 1 |
| D'Antonio, F | 1 |
| Di Bonaventura, G | 1 |
| Celentano, C | 1 |
| Liberati, M | 1 |
| Piccolomini, R | 1 |
| D'Antonio, D | 1 |
| Richardson, BA | 1 |
| Hassan, WM | 1 |
| Chohan, V | 1 |
| Lavreys, L | 1 |
| Mandaliya, K | 1 |
| Kiarie, J | 1 |
| Jaoko, W | 1 |
| Ndinya-Achola, JO | 1 |
| Baeten, JM | 1 |
| Kurth, AE | 1 |
| Holmes, KK | 1 |
| Seeney, SM | 1 |
| Grody, MH | 1 |
| Jordan, CA | 1 |
| Buckley, HR | 1 |
| Brooker, D | 1 |
| Stein, GE | 2 |
| Thomason, JL | 1 |
| Wermeling, DP | 1 |
| Bradley, B | 1 |
| Weinstein, L | 1 |
| Force, RW | 1 |
| Newman, SL | 1 |
| Flanigan, TP | 1 |
| Fisher, A | 1 |
| Rinaldi, MG | 1 |
| Stein, M | 1 |
| Vigilante, K | 1 |
| Holdcroft, C | 1 |
| van Heusden, AM | 2 |
| Merkus, HM | 2 |
| Euser, R | 1 |
| Verhoeff, A | 2 |
| Frega, A | 1 |
| Gallo, G | 1 |
| Di Renzi, F | 1 |
| Stolfi, G | 1 |
| Stentella, P | 1 |
| Inman, W | 1 |
| Pearce, G | 1 |
| Wilton, L | 1 |
| Dmitrieva, NV | 1 |
| Sokolova, EN | 1 |
| Makhova, EE | 1 |
| Petukhova, IN | 1 |
| Parmegiani, RM | 1 |
| Loebenberg, D | 1 |
| Cacciapuoti, A | 1 |
| Antonacci, B | 1 |
| Norris, C | 1 |
| Menzel, F | 1 |
| Moss, L | 1 |
| Yarosh-Tomaine, T | 1 |
| Hare, RS | 1 |
| Miller, GH | 1 |
| White, DJ | 1 |
| Johnson, EM | 2 |
| Warnock, DW | 2 |
| Vazquez, JA | 3 |
| Troke, PF | 3 |
| Kunzelmann, V | 1 |
| Rossner, D | 1 |
| Czaika, V | 1 |
| Hopp, M | 1 |
| Schmalreck, A | 1 |
| Sterry, W | 1 |
| Desai, PC | 1 |
| Johnson, BA | 1 |
| Mastroiacovo, P | 1 |
| Mazzone, T | 1 |
| Botto, LD | 1 |
| Serafini, MA | 1 |
| Finardi, A | 1 |
| Caramelli, L | 1 |
| Fusco, D | 1 |
| Campomori, A | 1 |
| Bonati, M | 1 |
| Wray, CM | 1 |
| Schuman, P | 3 |
| Capps, L | 1 |
| Peng, G | 2 |
| Vazquez, J | 1 |
| el-Sadr, W | 1 |
| Goldman, AI | 1 |
| Alston, B | 1 |
| Besch, CL | 1 |
| Vaughn, A | 1 |
| Thompson, MA | 1 |
| Cobb, MN | 1 |
| Kerkering, T | 1 |
| Kaplan, B | 1 |
| Rabinerson, D | 1 |
| Gibor, Y | 1 |
| Shinohara, YT | 1 |
| Tasker, SA | 1 |
| Baily, G | 1 |
| Fortun Abete, J | 1 |
| Hernanz Hermosa, JM | 1 |
| Lázaro Ochaita, P | 1 |
| Albukrek, D | 1 |
| Davidson, S | 1 |
| Merlob, P | 1 |
| Steele-Moore, L | 1 |
| Holloway, W | 1 |
| Neaton, JD | 1 |
| Ramos, AR | 1 |
| Vilgalys, R | 1 |
| Mitchell, TG | 1 |
| Matthews, P | 1 |
| Drew, SV | 1 |
| Low, L | 1 |
| Penk, A | 1 |
| Pittrow, L | 1 |
| Ringdahl, EN | 1 |
| Bornstein, J | 1 |
| Livnat, G | 1 |
| Stolar, Z | 1 |
| Abramovici, H | 1 |
| Ohmit, SE | 1 |
| Klein, RS | 1 |
| Mayer, K | 1 |
| Duerr, A | 1 |
| Rampalo, A | 1 |
| Birinci, A | 1 |
| Saniç, A | 1 |
| Durupinar, B | 1 |
| El-Din, SS | 1 |
| Reynolds, MT | 1 |
| Ashbee, HR | 1 |
| Barton, RC | 1 |
| Evans, EG | 1 |
| Mathema, B | 1 |
| Cross, E | 1 |
| Dun, E | 1 |
| Park, S | 1 |
| Bedell, J | 1 |
| Slade, B | 1 |
| Williams, M | 1 |
| Riley, L | 1 |
| Chaturvedi, V | 1 |
| Perlin, DS | 1 |
| Kapernick, PS | 1 |
| Wittes, H | 1 |
| Sirakov, M | 1 |
| Shopova, E | 1 |
| Stoianova, D | 1 |
| Krumov, G | 1 |
| Dermendzhiev, T | 1 |
| Laufer, B | 1 |
| Bender, HG | 1 |
| Slavin, MB | 1 |
| Benrubi, GI | 1 |
| Parker, R | 1 |
| Griffin, CR | 1 |
| Magee, MJ | 1 |
| Mazziotti, F | 1 |
| Cirillo, L | 1 |
| Arena, V | 1 |
| Cipriani, P | 1 |
| Ghezzi, C | 1 |
| Bresadola, M | 1 |
| Ragni, N | 1 |
| Donadio, C | 1 |
| Pellizzari, G | 1 |
| Patel, HS | 1 |
| Peters, MD | 1 |
| Smith, CL | 1 |
| Arilla, MC | 1 |
| Carbonero, JL | 1 |
| Schneider, J | 1 |
| Regúlez, P | 1 |
| Quindós, G | 1 |
| Pontón, J | 1 |
| Cisterna, R | 1 |
| Abbott, M | 1 |
| Hughes, DL | 1 |
| Patel, R | 1 |
| Kinghorn, GR | 1 |
| Osser, S | 1 |
| Haglund, A | 1 |
| Weström, L | 1 |
| Christensen, S | 1 |
| Mummaw, N | 1 |
| Zlatkov, V | 1 |
| Karag'ozov, I | 1 |
| Katsarova, M | 1 |
| Coldiron, BM | 1 |
| Manders, SM | 1 |
| Neuhaus, G | 1 |
| Pavic, N | 1 |
| Pletscher, M | 1 |
| Boag, FC | 1 |
| Houang, ET | 2 |
| Westrom, R | 1 |
| McCormack, SM | 1 |
| Lawrence, AG | 1 |
| Tanio, T | 1 |
| Ichise, K | 1 |
| Nakajima, T | 1 |
| Okuda, T | 1 |
| Hartzen, SH | 1 |
| Frimodt-Møller, N | 1 |
| Korner, B | 1 |
| Phillips, RJ | 1 |
| Watson, SA | 1 |
| McKay, FF | 1 |
| Corbeij, RS | 1 |
| Oosterbaan, HP | 1 |
| Stoot, JE | 1 |
| Ubachs, HM | 1 |
| Chappatte, O | 1 |
| Byrne, D | 1 |
| Macrae, PV | 1 |
| Thorpe, JE | 1 |
| Bottino, G | 1 |
| Menna, C | 1 |
| Herzog, RE | 1 |
| Ansmann, EB | 1 |
| Richardson, K | 2 |
| Cooper, K | 1 |
| Marriott, MS | 2 |
| Tarbit, MH | 1 |
| Whittle, PJ | 1 |
| Brammer, KW | 3 |
| Feczko, JM | 1 |
| Kutzer, E | 1 |
| Oittner, R | 1 |
| Leodolter, S | 1 |
| Burke, J | 1 |
| Cope, NJ | 1 |
| von Fraunhofer, NA | 1 |
| Williams, EW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 2, Multicenter, Randomized, Double-Blind, Double-Dummy, Active-Controlled, Dose-Finding Study to Compare the Safety and Efficacy of Oral Ibrexafungerp (SCY-078) vs. Oral Fluconazole in Subjects With Acute Vulvovaginal Candidiasis[NCT03253094] | Phase 2 | 186 participants (Actual) | Interventional | 2017-08-01 | Completed | ||
| A Phase 2A, Randomized, Double-Blind, Dose Ranging Study to Evaluate the Efficacy and Safety of VT-1161 Oral Tablets Compared to Fluconazole in the Treatment of Patients With Moderate to Severe Acute Vulvovaginal Candidiasis[NCT01891331] | Phase 2 | 55 participants (Actual) | Interventional | 2013-08-31 | Completed | ||
| A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of VT-1161 Oral Tablets in the Treatment of Patients With Recurrent Vulvovaginal Candidiasis[NCT02267382] | Phase 2 | 254 participants (Actual) | Interventional | 2015-02-10 | Completed | ||
| A Phase IIa Randomized, Active-controlled, Double-blind, Dose-escalation Study in Patients With Vulvovaginal Candidiasis to Evaluate Dose Response Relationship of Clinical Efficacy, Safety and Tolerability of Topically Administered ProF-001[NCT03115073] | Phase 2/Phase 3 | 84 participants (Actual) | Interventional | 2017-04-04 | Completed | ||
| A Randomized, Parallel-group Study of Terconazole Vaginal Suppository vs Fluconazole for the Treatment of Severe[NCT02180100] | Phase 4 | 140 participants (Actual) | Interventional | 2013-08-31 | Completed | ||
| A Multicenter Open-label Non-comparative Study Of Fluconazole For The Treatment Of Vulvovaginal Candidiasis.[NCT01806623] | Phase 3 | 157 participants (Actual) | Interventional | 2013-03-05 | Completed | ||
| Vaginal Colonization After Treatment With Lactobacillus in Women With BV or Candida Will That Increase the Cure Rate After Treatment With Clindamycin for BV and Flucnazole for Candida[NCT02295579] | 50 participants (Actual) | Observational [Patient Registry] | 2014-06-30 | Completed | |||
| An Case-controlled Randomized Study to the Efficacy of Clotrimazole Vaginal Tablet vs Fluconazole for Severe Vulvovaginal Candidiasis[NCT02180828] | Phase 4 | 240 participants (Actual) | Interventional | 2014-07-31 | Completed | ||
| Effect of Probiotics on GBS Colonization Status During Pregnancy: A Pilot Randomized Controlled Trial[NCT02528981] | 114 participants (Actual) | Interventional | 2015-08-31 | Completed | |||
| A Randomized, Prospective, Double-Blind Study Comparing Fluconazole With Placebo for Primary and Secondary Prophylaxis of Mucosal Candidiasis in HIV-Infected Women[NCT00000744] | 400 participants | Interventional | Completed | ||||
| "Vestibulitis Educational Seminar Trial Study"[NCT00278850] | 500 participants (Actual) | Observational | 2006-01-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"For this trial, therapeutic cure was defined as mycological AND clinical cure. Mycological cure was defined as a negative fungal culture for Candida species. Clinical cure was defined as all of the following:~complete resolution of signs and symptoms pertaining to vulvovaginal candidiasis;~any new sign or symptom observed at 28 days determined by investigator to not be related to vulvovaginal candidiasis;~no use of any other antifungal drug therapy for treatment of vulvovaginal irritation and/or pruritus by subject." (NCT01891331)
Timeframe: 4 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| VT-1161 300mg QD | 9 |
| VT-1161 600mg QD | 9 |
| VT-1161 600mg BID | 11 |
| Fluconazole 150mg | 10 |
"A culture-verified acute VVC episode was defined as a positive fungal culture for Candida species associated with a clinical signs and symptoms score of ≥3. To calculate the 'signs and symptoms' score, each vulvovaginal sign (erythema, edema, excoriation) and symptom (itching, burning, irritation) was scored using the following scale, with higher scores indicating a worse outcome.~0 = none (complete absence of any sign or symptom)~= mild (slight)~= moderate (definitely present)~= severe (marked, intense)" (NCT02267382)
Timeframe: 48 Weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| VT-1161 Low-dose 3-month | 2 |
| VT-1161 Low-dose 6-month | 3 |
| VT-1161 High-dose 3-month | 0 |
| VT-1161 High-dose 24-week | 2 |
| Placebo | 24 |
Based on candida culture (NCT02180100)
Timeframe: Between day 7-14 after treatment, an average of 10 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Terconazole Vaginal Suppository | 46 |
| Fluconazole | 47 |
Based on Candida culture (NCT02180100)
Timeframe: Between day 28-35 after treatment, an average of 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Terconazole Vaginal Suppository | 36 |
| Fluconazole | 35 |
Area under the concentration time-curve from zero to the last measured concentration (AUClast) for Vaginal Fluid Fluconazole Concentration Adjusted by Potassium in Vaginal Fluid (NCT01806623)
Timeframe: Before dosing and 2, 24, 48 and 168 hours after dosing
| Intervention | mcg*h/mL (Geometric Mean) |
|---|---|
| Fluconazole | 85.3 |
Area under the concentration time-curve from zero to the last measured concentration (AUClast) for Vaginal Fluid Fluconazole Concentration adjusted by Sample Weight (NCT01806623)
Timeframe: Before dosing and 2, 24, 48 and 168 hours after dosing
| Intervention | mcg*h/g (Geometric Mean) |
|---|---|
| Fluconazole | 79.5 |
Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast) (NCT01806623)
Timeframe: Before dosing and 2, 24, 48 and 168 hours after dosing
| Intervention | mcg*h/mL (Geometric Mean) |
|---|---|
| Fluconazole | 156.1 |
(NCT01806623)
Timeframe: Before dosing and 2, 24, 48 and 168 hours after dosing
| Intervention | mcg/mL (Geometric Mean) |
|---|---|
| Fluconazole | 1.53 |
(NCT01806623)
Timeframe: Before dosing and 2, 24, 48 and 168 hours after dosing
| Intervention | mcg/g (Geometric Mean) |
|---|---|
| Fluconazole | 1.33 |
(NCT01806623)
Timeframe: Before dosing and 2, 24, 48 and 168 hours after dosing
| Intervention | mcg/mL (Geometric Mean) |
|---|---|
| Fluconazole | 3.71 |
(NCT01806623)
Timeframe: Before dosing and 2, 24, 48 and 168 hours after dosing
| Intervention | hrs (Median) |
|---|---|
| Fluconazole | 20.5 |
(NCT01806623)
Timeframe: Before dosing and 2, 24, 48 and 168 hours after dosing
| Intervention | hours (Median) |
|---|---|
| Fluconazole | 20.5 |
(NCT01806623)
Timeframe: Before dosing and 2, 24, 48 and 168 hours after dosing
| Intervention | hours (Median) |
|---|---|
| Fluconazole | 1.9 |
"Scores of severity in signs and symptoms on each observation dates are compared with those before the treatment and the clinical efficacy is determined as Cure (the clinical symptom disappeared), Improvement (the clinical symptom was improved), Failure (the criteria for Cure and Improvement were not met, or other systemic antifungal drugs or local antifungal drugs were administered for the treatment of the disease to be examined) or Indeterminate (efficacy for each item was not determined for the reasons including failure to conduct the test, or other systemic antifungal agents or local antifungal drugs were administered for the treatment of infections other than the disease to be examined).~Cure and improvement rate was calculated based on the following formula, the number of participants assessed as Cure or Improvement over total participants excluding ones assessed as Indeterminate multiplied by 100." (NCT01806623)
Timeframe: Day 7, Day 14 and Day 28
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Day 7 (n=99) | Day 14 (n=101) | Day 28 (n=102) | |
| Fluconazole | 100.0 | 99.0 | 95.9 |
"Scores of severity in signs and symptoms at each observation dates were compared with those before the treatment and the clinical efficacy was determined as Cure (the clinical symptom disappeared), Improvement (the clinical symptom was improved: the total score of clinical symptom was reduced relative to the total score before the treatment), Failure (the criteria for Cure and Improvement were not met, or other systemic antifungal drugs or local antifungal drugs were administered for the treatment of the disease to be examined) or Indeterminate (efficacy for each item was not determined for the reasons including failure to conduct the test, or other systemic antifungal agents or local antifungal drugs were administered for the treatment of infections other than the disease to be examined).~Cure rate was calculated based on the following formula, the number of participants assessed as Cure over total participants excluding ones assessed as Indeterminate multiplied by 100." (NCT01806623)
Timeframe: Day 7, Day 14 and Day 28
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Day 7 (n=99) | Day 14 (n=101) | Day 28 (n=102) | |
| Fluconazole | 34.8 | 57.3 | 81.6 |
"Determined based on the results of culture of Candida as Eradication, Persistent or Indeterminate.~Eradication rate was calculated based on the following formula, the number of participants assessed as Eradication over total participants excluding ones assessed as Indeterminate multiplied by 100." (NCT01806623)
Timeframe: Day 7, Day 14 and Day 28
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Day 7 (n=95) | Day 14 (n=100) | Day 28 (n=102) | |
| Fluconazole | 95.7 | 89.8 | 85.9 |
"Therapeutic outcome was determined by combination of clinical efficacy and mycological efficacy for each participant as Effective, Ineffective or Indeterminate. The therapeutic outcome was considered as Effective when the clinical efficacy was Cure and the mycological efficacy was Eradication.~Primary evaluation of therapeutic outcome was on Day 28.~Response rate was calculated based on the following formula, the number of participants assessed as effective over total participants excluding ones assessed as indeterminate multiplied by 100." (NCT01806623)
Timeframe: Day 7, Day 14 and Day 28
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Day 7 (n=95) | Day 14 (n=100) | Day 28 (n=102) | |
| Fluconazole | 33.7 | 54.2 | 74.7 |
Sum of severity scores in vulvovaginal itching, vulvovaginal burning sensation, excoriation of vulva, vaginal discharge, vulva oedema, redness of vulva, vaginal redness, property of vaginal content. Higher scores show greater severity. Total Scores for Clinical Symptoms Severity range from 0 (best possible outcome) to 24 (worst possible outcome). (NCT01806623)
Timeframe: Day 1 (before dosing), Day 3, Day 7, Day 14 and Day 28
| Intervention | score on s scale (Mean) | ||||
|---|---|---|---|---|---|
| Day 1 (before dosing, n=102) | Day 3 (n=98) | Day 7 (n=93) | Day 14 (n=98) | Day 28 (n=99) | |
| Fluconazole | 11.0 | 4.5 | 1.8 | 0.8 | 0.4 |
Systemic: weak, palpitation, tachycardia, migraine, headache, dizzy, rhinorrhea, numb, dizziness, fatigue. (NCT02180828)
Timeframe: at day 7-14 follow up
| Intervention | participants (Number) |
|---|---|
| Clotrimazole Vaginal Tablet | 1 |
| Fluconazole | 9 |
Vulvovaginal pruritus, burning, irritation, and bleeding (NCT02180828)
Timeframe: at day 7-14 follow up
| Intervention | participants (Number) |
|---|---|
| Clotrimazole Vaginal Tablet | 12 |
| Fluconazole | 1 |
Gastrointestinal tract: abdominal pain, diarrhoea, nausea (NCT02180828)
Timeframe: at day 7-14 follow up
| Intervention | participants (Number) |
|---|---|
| Clotrimazole Vaginal Tablet | 3 |
| Fluconazole | 3 |
Skin sensitivity, urticaria rash, erythematous rash, irritation (NCT02180828)
Timeframe: at day 7-14 follow up
| Intervention | participants (Number) |
|---|---|
| Clotrimazole Vaginal Tablet | 0 |
| Fluconazole | 3 |
The clinical cure rates of clotrimazole and fluconazol: Clinical cure was defined as the resolution of symptoms present at baseline with a total severity score of ≤2. Improvement was defined as considerable reduction in the severity of baseline signs and symptoms with a decrease in the total score by ≥50%.Patients not clinically cured or showing improvement were considered clinical failures. (NCT02180828)
Timeframe: 7-14 days after treatment (=visit 2)
| Intervention | participants (Number) |
|---|---|
| Clotrimazole Vaginal Tablet | 102 |
| Fluconazole | 98 |
The clinical cure rates of clotrimazole and fluconazol (NCT02180828)
Timeframe: at days 30-35 follow-up
| Intervention | participants (Number) |
|---|---|
| Clotrimazole Vaginal Tablet | 82 |
| Fluconazole | 85 |
Mycological cure of clotrimazole group and fluconazole group (NCT02180828)
Timeframe: at days 7-14 follow-up
| Intervention | participants (Number) |
|---|---|
| Clotrimazole Vaginal Tablet | 90 |
| Fluconazole | 81 |
Mycological cure of clotrimazole group and fluconazole group: Mycological cure or failure was referred to as Candida negative or positive,respectively, on Candida culture at follow-up visits. (NCT02180828)
Timeframe: at days30-35 follow-up
| Intervention | participants (Number) |
|---|---|
| Clotrimazole Vaginal Tablet | 62 |
| Fluconazole | 61 |
Total adverse events(cases) (NCT02180828)
Timeframe: at day 7-14 follow up
| Intervention | participants (Number) |
|---|---|
| Clotrimazole Vaginal Tablet | 16 |
| Fluconazole | 12 |
39 reviews available for fluconazole and Candidiasis, Vulvovaginal
| Article | Year |
|---|---|
Vulvovaginal Candidiasis: A Review of the Evidence for the 2021 Centers for Disease Control and Prevention of Sexually Transmitted Infections Treatment Guidelines.
Topics: Antifungal Agents; Candida albicans; Candidiasis, Vulvovaginal; Centers for Disease Control and Prev | 2022 |
Ibrexafungerp in the Treatment of Vulvovaginal Candidiasis.
Topics: Antifungal Agents; Candidiasis, Vulvovaginal; Female; Fluconazole; Humans; Imidazoles; Triterpenes | 2023 |
Molecular epidemiology, antifungal susceptibility, and ERG11 gene mutation of Candida species isolated from vulvovaginal candidiasis: Comparison between recurrent and non-recurrent infections.
Topics: Antifungal Agents; Candida; Candida albicans; Candida glabrata; Candida parapsilosis; Candida tropic | 2022 |
Management of recurrent vulvovaginal candidosis: Narrative review of the literature and European expert panel opinion.
Topics: Antifungal Agents; Azoles; Candida; Candida albicans; Candidiasis, Vulvovaginal; Female; Fluconazole | 2022 |
Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis: Design, Development and Place in Therapy.
Topics: Antifungal Agents; Azoles; Candida albicans; Candidiasis, Vulvovaginal; Female; Fluconazole; Humans; | 2023 |
A longitudinal study on fluconazole resistance in Candida albicans vaginal isolates.
Topics: Antifungal Agents; Candida albicans; Candidiasis, Vulvovaginal; Drug Resistance, Fungal; Female; Flu | 2023 |
Interplay of the microbiome and antifungal therapy in recurrent vulvovaginal candidiasis (RVVC): A narrative review.
Topics: Adult; Antifungal Agents; Candida albicans; Candidiasis, Vulvovaginal; Female; Fluconazole; Humans; | 2023 |
Beyond fluconazole: A review of vulvovaginal candidiasis diagnosis and treatment.
Topics: Candidiasis, Vulvovaginal; Critical Care; Female; Fluconazole; Humans; Vagina | 2023 |
The safety of oral fluconazole during the first trimester of pregnancy: a systematic review and meta-analysis.
Topics: Abnormalities, Drug-Induced; Administration, Oral; Antifungal Agents; Candidiasis, Vulvovaginal; Cra | 2019 |
Maternal use of fluconazole and congenital malformations in the progeny: A meta-analysis of the literature.
Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Antifungal Agents; Candidiasis, Vulvovaginal; Do | 2021 |
Probiotics for vulvovaginal candidiasis in non-pregnant women.
Topics: Administration, Intravaginal; Antifungal Agents; Candidiasis, Vulvovaginal; Clotrimazole; Female; Fl | 2017 |
Current treatment options for vulvovaginal candidiasis caused by azole-resistant Candida species.
Topics: 14-alpha Demethylase Inhibitors; Antifungal Agents; Boric Acids; Candida; Candidiasis, Vulvovaginal; | 2018 |
Combined systemic (fluconazole) and topical (metronidazole + clotrimazole) therapy for a new approach to the treatment and prophylaxis of recurrent candidiasis.
Topics: Administration, Oral; Administration, Topical; Antifungal Agents; Candidiasis, Vulvovaginal; Clotrim | 2019 |
Exposure to fluconazole and risk of congenital malformations in the offspring: A systematic review and meta-analysis.
Topics: Abnormalities, Drug-Induced; Antifungal Agents; Candidiasis, Vulvovaginal; Craniofacial Abnormalitie | 2015 |
Treatment of vulvovaginal candidiasis: a review of the literature.
Topics: Administration, Oral; Antifungal Agents; Candidiasis, Vulvovaginal; Female; Fluconazole; Humans; Pro | 2015 |
Candidiasis (vulvovaginal).
Topics: Antifungal Agents; Candidiasis, Vulvovaginal; Complementary Therapies; Female; Fluconazole; Humans; | 2015 |
[Genital candidiasis].
Topics: Antifungal Agents; Candida albicans; Candidiasis, Vulvovaginal; Diagnosis, Differential; Dosage Form | 2009 |
Candidiasis (vulvovaginal).
Topics: Acute Disease; Administration, Oral; Candida albicans; Candidiasis, Vulvovaginal; Evidence-Based Med | 2010 |
Interventions for prevention and treatment of vulvovaginal candidiasis in women with HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Antifungal Agents; Candidiasis, Vulvovaginal; Clotrima | 2011 |
Weekly fluconazole therapy for recurrent vulvovaginal candidiasis: a systematic review and meta-analysis.
Topics: Antibiotic Prophylaxis; Antifungal Agents; Candidiasis, Vulvovaginal; Drug Administration Schedule; | 2013 |
[Vaginal candidiasis--treatment protocols using miconazole and fluconazole].
Topics: Antifungal Agents; Candidiasis, Vulvovaginal; Diagnosis, Differential; Female; Fluconazole; Humans; | 2003 |
Candidiasis (vulvovaginal).
Topics: Antifungal Agents; Candidiasis, Vulvovaginal; Female; Fluconazole; Humans; Imidazoles; Itraconazole; | 2003 |
Fluconazole for the treatment of candidiasis: 15 years experience.
Topics: Animals; Antibiotic Prophylaxis; Antifungal Agents; Candidiasis; Candidiasis, Oral; Candidiasis, Vul | 2004 |
Candidiasis (vulvovaginal).
Topics: Antifungal Agents; Candidiasis, Vulvovaginal; Female; Fluconazole; Humans; Imidazoles; Itraconazole; | 2003 |
Candidiasis (vulvovaginal).
Topics: Antifungal Agents; Candidiasis, Vulvovaginal; Female; Fluconazole; Humans; Itraconazole; Nystatin; S | 2004 |
Candidiasis (vulvovaginal).
Topics: Antifungal Agents; Candidiasis, Vulvovaginal; Female; Fluconazole; Humans; Itraconazole; Ketoconazol | 2005 |
Itraconazole vs fluconazole for the treatment of uncomplicated acute vaginal and vulvovaginal candidiasis in nonpregnant women: a metaanalysis of randomized controlled trials.
Topics: Administration, Oral; Antifungal Agents; Candidiasis, Vulvovaginal; Female; Fluconazole; Humans; Itr | 2008 |
Two cases of vaginitis caused by itraconazole-resistant Saccharomyces cerevisiae and a review of recently published studies.
Topics: Adult; Antifungal Agents; Candidiasis, Vulvovaginal; Diagnosis, Differential; Drug Resistance, Funga | 2008 |
Fluconazole: its properties and efficacy in vaginal candidiasis.
Topics: Antifungal Agents; Candidiasis, Vulvovaginal; Female; Fluconazole; Humans | 1996 |
Oral fluconazole for vaginal candidiasis.
Topics: Administration, Oral; Antifungal Agents; Candidiasis, Vulvovaginal; Female; Fluconazole; Humans | 1996 |
[Diagnosis, treatment and prevention of infections caused by fungi in HIV-positive patients].
Topics: Adult; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Aspergillosis; Cand | 1995 |
[Superficial mycoses in immunosuppressed patients].
Topics: Adult; Antifungal Agents; Candidiasis, Cutaneous; Candidiasis, Oral; Candidiasis, Vulvovaginal; Chil | 1995 |
[Fluconazole administration during pregnancy].
Topics: Abnormalities, Drug-Induced; Antifungal Agents; Candidiasis; Candidiasis, Vulvovaginal; Female; Fluc | 1998 |
Recurrent vaginal thrush and soreness.
Topics: Adult; Anti-Infective Agents, Local; Antifungal Agents; Candidiasis, Vulvovaginal; Clotrimazole; Dia | 1999 |
Treatment of recurrent vulvovaginal candidiasis.
Topics: Antifungal Agents; Boric Acids; Candidiasis, Vulvovaginal; Clotrimazole; Drug Interactions; Female; | 2000 |
[Current developments in antimycotic therapy in gynecology and obstetrics].
Topics: Animals; Antifungal Agents; Candidiasis, Vulvovaginal; Dose-Response Relationship, Drug; Female; Flu | 1992 |
[Comparative clinical study of a new imidazole molecule (fluconazole) and ketaconazole in the treatment of Candida albicans vulvovaginitis].
Topics: Adult; Candidiasis, Vulvovaginal; Drug Evaluation; Female; Fluconazole; Humans; Ketoconazole; Middle | 1992 |
Is there a role for fluconazole in the treatment of vulvovaginal candidiasis?
Topics: Candidiasis, Vulvovaginal; Female; Fluconazole; Humans | 1992 |
Fluconazole and itraconazole for vulvo-vaginal candidosis.
Topics: Antifungal Agents; Candidiasis, Vulvovaginal; Female; Fluconazole; Humans; Itraconazole; Ketoconazol | 1990 |
59 trials available for fluconazole and Candidiasis, Vulvovaginal
| Article | Year |
|---|---|
Phase 2 Randomized Study of Oral Ibrexafungerp Versus Fluconazole in Vulvovaginal Candidiasis.
Topics: Administration, Oral; Antifungal Agents; Candidiasis, Vulvovaginal; Female; Fluconazole; Glycosides; | 2022 |
Phase 3 study evaluating the safety and efficacy of oteseconazole in the treatment of recurrent vulvovaginal candidiasis and acute vulvovaginal candidiasis infections.
Topics: Administration, Oral; Antifungal Agents; Candidiasis, Vulvovaginal; Female; Fluconazole; Humans; Inf | 2022 |
Comparing the Effect of Probiotic and Fluconazole on Treatment and Recurrence of Vulvovaginal Candidiasis: a Triple-Blinded Randomized Controlled Trial.
Topics: Antifungal Agents; Candidiasis, Vulvovaginal; Capsules; Female; Fluconazole; Humans; Iran; Probiotic | 2023 |
Quality of life in women with chronic recurrent vulvovaginal candidosis: A sub-analysis of the prospective multicentre phase IIb/III Prof-001 study.
Topics: Candidiasis, Chronic Mucocutaneous; Candidiasis, Vulvovaginal; Female; Fluconazole; Humans; Male; Pr | 2023 |
Efficacy of a medical grade honey formulation (L-Mesitran) in comparison with fluconazole in the treatment of women with recurrent vulvovaginal candidiasis: protocol for a randomised controlled trial (HONEY STUDY).
Topics: Candidiasis, Vulvovaginal; Female; Fluconazole; Honey; Hospitals, University; Humans; Multicenter St | 2023 |
A Randomized Phase 2 Study of VT-1161 for the Treatment of Acute Vulvovaginal Candidiasis.
Topics: Administration, Oral; Antifungal Agents; Candidiasis, Vulvovaginal; Female; Fluconazole; Humans; Pyr | 2021 |
A phase 2, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of orally administered VT-1161 in the treatment of recurrent vulvovaginal candidiasis.
Topics: 14-alpha Demethylase Inhibitors; Administration, Oral; Adult; Antifungal Agents; Candidiasis, Vulvov | 2018 |
Sexual behaviour and extra-genital colonisation in women treated for recurrent Candida vulvo-vaginitis.
Topics: Adult; Antifungal Agents; Candida; Candidiasis, Vulvovaginal; Female; Fluconazole; Humans; Recurrenc | 2018 |
CD101 Topical Compared With Oral Fluconazole for Acute Vulvovaginal Candidiasis: A Randomized Controlled Trial.
Topics: Administration, Oral; Administration, Topical; Adult; Antifungal Agents; Candidiasis, Vulvovaginal; | 2019 |
Dermasilk® briefs in recurrent vulvovaginal candidosis. An alternative option in long-lasting disease.
Topics: Candidiasis, Vulvovaginal; Double-Blind Method; Fluconazole; Humans; Recurrence | 2013 |
Local Probiotic Therapy for Vaginal Candida albicans Infections.
Topics: Administration, Oral; Adolescent; Adult; Antifungal Agents; Candida albicans; Candidiasis, Vulvovagi | 2015 |
Miconazole nitrate vaginal suppository 1,200 mg versus oral fluconazole 150 mg in treating severe vulvovaginal candidiasis.
Topics: Administration, Intravaginal; Adult; Antifungal Agents; Candidiasis, Vulvovaginal; Case-Control Stud | 2015 |
A randomized clinical trial of the efficacy and safety of terconazole vaginal suppository versus oral fluconazole for treating severe vulvovaginal candidiasis.
Topics: Administration, Oral; Adolescent; Adult; Antifungal Agents; Candidiasis, Vulvovaginal; Case-Control | 2015 |
Efficacy and safety of a single oral 150 mg dose of fluconazole for the treatment of vulvovaginal candidiasis in Japan.
Topics: Administration, Oral; Adolescent; Adult; Antifungal Agents; Candidiasis, Vulvovaginal; Female; Fluco | 2015 |
Vaginal colonisation by probiotic lactobacilli and clinical outcome in women conventionally treated for bacterial vaginosis and yeast infection.
Topics: Administration, Intravaginal; Adult; Anti-Bacterial Agents; Antifungal Agents; Candidiasis, Vulvovag | 2015 |
Comparison of the therapeutic effects of Garcin(®) and fluconazole on Candida vaginitis.
Topics: Adolescent; Adult; Antifungal Agents; Candida; Candidiasis, Vulvovaginal; Female; Fluconazole; Garli | 2015 |
FLUCONAZOLE AND BORIC ACID FOR TREATMENT OF VAGINAL CANDIDIASIS--NEW WORDS ABOUT OLD ISSUE.
Topics: Administration, Intravaginal; Administration, Oral; Adult; Antifungal Agents; Boric Acids; Candida; | 2013 |
The efficacy and safety of clotrimazole vaginal tablet vs. oral fluconazole in treating severe vulvovaginal candidiasis.
Topics: Administration, Oral; Adolescent; Adult; Antifungal Agents; Candida; Candidiasis, Vulvovaginal; Clot | 2016 |
Comparing the Recurrence of Vulvovaginal Candidiasis in Patients Undergoing Prophylactic Treatment with Probiotic and Placebo During the 6 Months.
Topics: Antifungal Agents; Candidiasis, Vulvovaginal; Double-Blind Method; Female; Fluconazole; Humans; Prob | 2016 |
Efficacy of vitamin B complex as an adjuvant therapy for the treatment of complicated vulvovaginal candidiasis: An in vivo and in vitro study.
Topics: Adult; Animals; Antifungal Agents; Candida; Candidiasis, Vulvovaginal; Drug Therapy, Combination; Fe | 2017 |
Microemulsion based vaginal gel of fluconazole: formulation, in vitro and in vivo evaluation.
Topics: Adhesiveness; Administration, Intravaginal; Animals; Antifungal Agents; Candidiasis, Vulvovaginal; C | 2009 |
Improved treatment of vulvovaginal candidiasis with fluconazole plus probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14.
Topics: Adolescent; Adult; Antifungal Agents; Candida; Candidiasis, Vulvovaginal; Double-Blind Method; Femal | 2009 |
[Comparison of clinical efficacy and safety of domestic generic and original fluconazoles in the treatment of pregnant women with vulvovaginal candidiasis].
Topics: Adult; Antifungal Agents; Candidiasis, Vulvovaginal; Drugs, Generic; Female; Fluconazole; Humans; Pr | 2008 |
Use of Dermasilk briefs in recurrent vulvovaginal candidosis: safety and effectiveness.
Topics: Adult; Antifungal Agents; Candidiasis, Vulvovaginal; Clothing; Female; Fluconazole; Humans; Secondar | 2012 |
Oral fluconazole 150 mg single dose versus intra-vaginal clotrimazole treatment of acute vulvovaginal candidiasis.
Topics: Acute Disease; Administration, Intravaginal; Administration, Oral; Adult; Antifungal Agents; Candidi | 2011 |
[Short-course treatment of vulvovaginal candidiasis: comparative study of fluconazole and intra-vaginal fenticonazole].
Topics: Administration, Intravaginal; Adult; Antifungal Agents; Candidiasis, Vulvovaginal; Drug Administrati | 2012 |
Fluconazole 150 mg single dose versus itraconazole 200 mg per day for 3 days in the treatment of acute vaginal candidiasis: a double-blind randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Antifungal Agents; Candidiasis, Vulvovaginal; Double-Bli | 2003 |
Correlation of in vitro itraconazole and fluconazole susceptibility with clinical outcome for patients with vulvovaginal candidiasis.
Topics: Antifungal Agents; Candida albicans; Candidiasis, Vulvovaginal; Female; Fluconazole; Humans; Itracon | 2004 |
A clinical multicenter study comparing efficacy and tolerability of topical combination therapy with clotrimazole (Canesten, two formats) with oral single dose fluconazole (Diflucan) in vulvovaginal mycoses.
Topics: Administration, Intravaginal; Administration, Oral; Administration, Topical; Antifungal Agents; Cand | 2004 |
[Comparative study of itraconazole and fluconazole therapy in vaginal candidosis].
Topics: Administration, Oral; Adolescent; Adult; Antifungal Agents; Candidiasis, Vulvovaginal; Drug Administ | 2004 |
Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis.
Topics: Administration, Oral; Adult; Antifungal Agents; Candida albicans; Candida glabrata; Candidiasis, Vul | 2004 |
[Treatment of chronic recurrent vulvovaginal candidiasis with fluconazole (fungolon--Actavis)].
Topics: Administration, Oral; Adult; Antifungal Agents; Candidiasis, Vulvovaginal; Chronic Disease; Female; | 2005 |
An evaluation of butoconazole nitrate 2% site release vaginal cream (Gynazole-1) compared to fluconazole 150 mg tablets (Diflucan) in the time to relief of symptoms in patients with vulvovaginal candidiasis.
Topics: Administration, Topical; Adult; Aged; Antifungal Agents; Candidiasis, Vulvovaginal; Drug Administrat | 2005 |
Short-term therapy for mixed vaginal infections.
Topics: Administration, Oral; Antifungal Agents; Antiprotozoal Agents; Antitrichomonal Agents; Candidiasis, | 2006 |
Fluconazole versus 3-day clotrimazole in the treatment of sporadic and recurrent vulvovaginal candidiasis.
Topics: Antifungal Agents; Candidiasis, Vulvovaginal; Clotrimazole; Drug Administration Schedule; Female; Fl | 2006 |
Prevalence of Candida glabrata and its response to boric acid vaginal suppositories in comparison with oral fluconazole in patients with diabetes and vulvovaginal candidiasis.
Topics: Administration, Oral; Adult; Antifungal Agents; Boric Acids; Candida albicans; Candida glabrata; Can | 2007 |
Prolonged (3-month) mycological cure rate after boric acid suppositories in diabetic women with vulvovaginal candidiasis.
Topics: Administration, Oral; Adult; Antifungal Agents; Boric Acids; Candidiasis, Vulvovaginal; Diabetes Mel | 2007 |
Improvement of vaginal health for Kenyan women at risk for acquisition of human immunodeficiency virus type 1: results of a randomized trial.
Topics: Adolescent; Adult; Anti-Infective Agents; Antifungal Agents; Candidiasis, Vulvovaginal; Female; Fluc | 2008 |
Single oral dose fluconazole compared with conventional clotrimazole topical therapy of Candida vaginitis. Fluconazole Vaginitis Study Group.
Topics: Acute Disease; Administration, Oral; Administration, Topical; Adolescent; Adult; Candidiasis, Vulvov | 1995 |
A randomized, comparative study of a single oral dose of fluconazole versus a single topical dose of clotrimazole in the treatment of vaginal candidosis among general practitioners and gynaecologists.
Topics: Administration, Intravaginal; Administration, Oral; Adolescent; Adult; Aged; Candidiasis, Vulvovagin | 1994 |
Persistent vulvovaginal candidiasis: systemic treatment with oral fluconazole.
Topics: Administration, Oral; Adolescent; Adult; Candidiasis, Vulvovaginal; Drug Administration Schedule; Fe | 1994 |
[A trial of the use of diflucan (fluconazole) in patients with vaginal candidiasis].
Topics: Administration, Oral; Adult; Candida albicans; Candidiasis, Vulvovaginal; Female; Fluconazole; Gardn | 1993 |
[Prerequisites for effective therapy of chronic recurrent vaginal candidiasis].
Topics: Adolescent; Adult; Aged; Antifungal Agents; Candida; Candida albicans; Candidiasis, Vulvovaginal; Ch | 1996 |
Weekly fluconazole for the prevention of mucosal candidiasis in women with HIV infection. A randomized, double-blind, placebo-controlled trial. Terry Beirn Community Programs for Clinical Research on AIDS.
Topics: Adult; AIDS-Related Opportunistic Infections; Antifungal Agents; Candida albicans; Candidiasis, Oral | 1997 |
Evolution of vaginal Candida species recovered from human immunodeficiency virus-infected women receiving fluconazole prophylaxis: the emergence of Candida glabrata? Terry Beirn Community Programs for Clinical Research in AIDS (CPCRA).
Topics: AIDS-Related Opportunistic Infections; Antibiotic Prophylaxis; Antifungal Agents; Candida; Candida a | 1999 |
Pure versus complicated vulvar vestibulitis: a randomized trial of fluconazole treatment.
Topics: Antifungal Agents; Candidiasis, Vulvovaginal; Female; Fluconazole; Humans; Inflammation; Vulvar Dise | 2000 |
Treatment of complicated Candida vaginitis: comparison of single and sequential doses of fluconazole.
Topics: Adult; Antifungal Agents; Candida; Candida albicans; Candidiasis, Vulvovaginal; Double-Blind Method; | 2001 |
Single dose oral fluconazole vs intravaginal terconazole in treatment of Candida vaginitis. Comparison and pilot study.
Topics: Administration, Intravaginal; Administration, Oral; Adolescent; Adult; Antifungal Agents; Candidiasi | 1992 |
[Comparative clinical study of a new imidazole molecule (fluconazole) and ketaconazole in the treatment of Candida albicans vulvovaginitis].
Topics: Adult; Candidiasis, Vulvovaginal; Drug Evaluation; Female; Fluconazole; Humans; Ketoconazole; Middle | 1992 |
Treatment of candidal vaginitis. A prospective randomized investigator-blind multicenter study comparing topically applied econazole with oral fluconazole.
Topics: Administration, Intravaginal; Administration, Oral; Adult; Candidiasis, Vulvovaginal; Econazole; Fem | 1991 |
Comparative study of fluconazole and clotrimazole in the treatment of vulvovaginal candidiasis.
Topics: Administration, Intravaginal; Administration, Oral; Adolescent; Adult; Aged; Candidiasis, Vulvovagin | 1991 |
Comparison of vaginal flora after treatment with a clotrimazole 500 mg vaginal pessary or a fluconazole 150 mg capsule for vaginal candidosis.
Topics: Administration, Oral; Bacteria; Candida; Candidiasis, Vulvovaginal; Clotrimazole; Colony Count, Micr | 1991 |
[Fluconazole. A new antimycotic for systemic use].
Topics: Antifungal Agents; Candida albicans; Candidiasis, Vulvovaginal; Female; Fluconazole; Humans; Multice | 1990 |
An open multicentre study of the efficacy and safety of a single dose of fluconazole 150 mg in the treatment of vaginal candidiasis in general practice.
Topics: Administration, Oral; Adolescent; Adult; Aged; Candidiasis, Vulvovaginal; Family Practice; Female; F | 1990 |
Single-dose oral fluconazole versus single-dose topical miconazole for the treatment of acute vulvovaginal candidosis.
Topics: Acute Disease; Administration, Intravaginal; Administration, Oral; Adult; Candidiasis, Vulvovaginal; | 1990 |
A comparison of single-dose oral fluconazole with 3-day intravaginal clotrimazole in the treatment of vaginal candidiasis. Report of an international multicentre trial.
Topics: Administration, Intravaginal; Administration, Oral; Adult; Antifungal Agents; Candidiasis, Vulvovagi | 1989 |
Treatment of vaginal candidiasis with a single oral dose of fluconazole. Multicentre Study Group.
Topics: Administration, Oral; Adolescent; Adult; Aged; Candida albicans; Candidiasis, Vulvovaginal; Clinical | 1988 |
Single-dose oral fluconazole in the treatment of vaginal candidosis.
Topics: Administration, Oral; Administration, Topical; Antifungal Agents; Candidiasis, Vulvovaginal; Clinica | 1988 |
A comparison of fluconazole and ketoconazole in the oral treatment of vaginal candidiasis; report of a double-blind multicentre trial.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antifungal Agents; Candidiasis, Vulvovaginal; Clinica | 1988 |
190 other studies available for fluconazole and Candidiasis, Vulvovaginal
| Article | Year |
|---|---|
Antifungal resistance of Candida glabrata vaginal isolates and development of a quantitative reverse transcription-PCR-based azole susceptibility assay.
Topics: Antifungal Agents; Azoles; Candida glabrata; Candidiasis, Vulvovaginal; Drug Resistance, Fungal; Fem | 2008 |
Fenticonazole activity measured by the methods of the European Committee on Antimicrobial Susceptibility Testing and CLSI against 260 Candida vulvovaginitis isolates from two European regions and annotations on the prevalent genotypes.
Topics: Adult; Antifungal Agents; Candida albicans; Candida glabrata; Candidiasis, Vulvovaginal; Cluster Ana | 2009 |
Correlation between azole susceptibilities, genotypes, and ERG11 mutations in Candida albicans isolates associated with vulvovaginal candidiasis in China.
Topics: Antifungal Agents; Azoles; Candida albicans; Candidiasis, Vulvovaginal; China; Cytochrome P-450 Enzy | 2010 |
Oteseconazole: an advance in treatment of recurrent vulvovaginal candidiasis.
Topics: Antifungal Agents; Candida albicans; Candidiasis, Vulvovaginal; Female; Fluconazole; Humans; Recurre | 2021 |
The liquid Kangfuxin (KFX) has efficient antifungal activity and can be used in the treatment of vulvovaginal candidiasis in mice.
Topics: Animals; Antifungal Agents; Candida albicans; Candidiasis, Vulvovaginal; Female; Fluconazole; Materi | 2022 |
Genotyping and Drug Resistance Profile of Clinical Isolates of Candida albicans from Vulvovaginal Candidiasis in the Eastern China.
Topics: Anidulafungin; Antifungal Agents; Candida; Candida albicans; Candidiasis, Vulvovaginal; Drug Resista | 2022 |
Differential Response of
Topics: Antifungal Agents; Boric Acids; Candida; Candida albicans; Candidiasis, Vulvovaginal; Drug Resistanc | 2022 |
Prevalence and species distribution of microorganisms isolated among non-pregnant women affected by vulvovaginal candidiasis: A retrospective study over a 20 year-period.
Topics: Amphotericin B; Antifungal Agents; Candida; Candida albicans; Candida glabrata; Candida parapsilosis | 2022 |
Determining Susceptibility in
Topics: Antifungal Agents; Azoles; Candida; Candida albicans; Candidiasis, Vulvovaginal; Drug Resistance, Fu | 2022 |
Bioactive compounds with antifungal activity against pathogens isolated from pregnant woman: Gallesia integrifolia (garlic wood) is a promising treatment for vulvovaginal candidiasis.
Topics: Antifungal Agents; Candida; Candida albicans; Candida glabrata; Candida tropicalis; Candidiasis, Vul | 2022 |
First detection of mutated ERG11 gene in vulvovaginal Candida albicans isolates at Ouagadougou/Burkina Faso.
Topics: Antifungal Agents; Azoles; Burkina Faso; Candida albicans; Candidiasis, Vulvovaginal; Cytochrome P-4 | 2022 |
Ibrexafungerp: A new triterpenoid antifungal.
Topics: Adult; Antifungal Agents; Candidiasis, Vulvovaginal; Child; Echinocandins; Female; Fluconazole; Huma | 2022 |
Microbiological and molecular screening of
Topics: Antifungal Agents; Candida; Candida albicans; Candidiasis, Vulvovaginal; Female; Fluconazole; Humans | 2022 |
Vulvovaginal candidiasis in Iranian women: Molecular identification and antifungal susceptibility pattern.
Topics: Antifungal Agents; Candida albicans; Candidiasis, Vulvovaginal; Cross-Sectional Studies; Drug Resist | 2022 |
Biased Genotype Distributions of Candida albicans Strains Associated with 649 Clinical Vulvovaginal Candidiasis in China.
Topics: Amphotericin B; Antifungal Agents; Candida albicans; Candidiasis, Vulvovaginal; Drug Resistance, Fun | 2022 |
Outcomes and experiences of using oral voriconazole with or without concomitant topical agents to treat refractory vulvovaginal yeast infections.
Topics: Antifungal Agents; Candidiasis, Vulvovaginal; Female; Fluconazole; Humans; Retrospective Studies; Sa | 2022 |
In Vitro Antifungal Activity of Azoles and Other Antifungal Agents Against Pathogenic Yeasts from Vulvovaginal Candidiasis in China.
Topics: Antifungal Agents; Azoles; Candida; Candida albicans; Candida glabrata; Candidiasis, Vulvovaginal; C | 2023 |
In Vitro Antifungal Activity of Azoles and Other Antifungal Agents Against Pathogenic Yeasts from Vulvovaginal Candidiasis in China.
Topics: Antifungal Agents; Azoles; Candida; Candida albicans; Candida glabrata; Candidiasis, Vulvovaginal; C | 2023 |
In Vitro Antifungal Activity of Azoles and Other Antifungal Agents Against Pathogenic Yeasts from Vulvovaginal Candidiasis in China.
Topics: Antifungal Agents; Azoles; Candida; Candida albicans; Candida glabrata; Candidiasis, Vulvovaginal; C | 2023 |
In Vitro Antifungal Activity of Azoles and Other Antifungal Agents Against Pathogenic Yeasts from Vulvovaginal Candidiasis in China.
Topics: Antifungal Agents; Azoles; Candida; Candida albicans; Candida glabrata; Candidiasis, Vulvovaginal; C | 2023 |
In Vitro Antifungal Activity of Azoles and Other Antifungal Agents Against Pathogenic Yeasts from Vulvovaginal Candidiasis in China.
Topics: Antifungal Agents; Azoles; Candida; Candida albicans; Candida glabrata; Candidiasis, Vulvovaginal; C | 2023 |
In Vitro Antifungal Activity of Azoles and Other Antifungal Agents Against Pathogenic Yeasts from Vulvovaginal Candidiasis in China.
Topics: Antifungal Agents; Azoles; Candida; Candida albicans; Candida glabrata; Candidiasis, Vulvovaginal; C | 2023 |
In Vitro Antifungal Activity of Azoles and Other Antifungal Agents Against Pathogenic Yeasts from Vulvovaginal Candidiasis in China.
Topics: Antifungal Agents; Azoles; Candida; Candida albicans; Candida glabrata; Candidiasis, Vulvovaginal; C | 2023 |
In Vitro Antifungal Activity of Azoles and Other Antifungal Agents Against Pathogenic Yeasts from Vulvovaginal Candidiasis in China.
Topics: Antifungal Agents; Azoles; Candida; Candida albicans; Candida glabrata; Candidiasis, Vulvovaginal; C | 2023 |
In Vitro Antifungal Activity of Azoles and Other Antifungal Agents Against Pathogenic Yeasts from Vulvovaginal Candidiasis in China.
Topics: Antifungal Agents; Azoles; Candida; Candida albicans; Candida glabrata; Candidiasis, Vulvovaginal; C | 2023 |
Activity of Novel Ultrashort Cyclic Lipopeptides against Biofilm of
Topics: Animals; Anti-Bacterial Agents; Biofilms; Candida; Candida albicans; Candidiasis, Vulvovaginal; Dise | 2022 |
Activity of Novel Ultrashort Cyclic Lipopeptides against Biofilm of
Topics: Animals; Anti-Bacterial Agents; Biofilms; Candida; Candida albicans; Candidiasis, Vulvovaginal; Dise | 2022 |
Activity of Novel Ultrashort Cyclic Lipopeptides against Biofilm of
Topics: Animals; Anti-Bacterial Agents; Biofilms; Candida; Candida albicans; Candidiasis, Vulvovaginal; Dise | 2022 |
Activity of Novel Ultrashort Cyclic Lipopeptides against Biofilm of
Topics: Animals; Anti-Bacterial Agents; Biofilms; Candida; Candida albicans; Candidiasis, Vulvovaginal; Dise | 2022 |
Activity of Novel Ultrashort Cyclic Lipopeptides against Biofilm of
Topics: Animals; Anti-Bacterial Agents; Biofilms; Candida; Candida albicans; Candidiasis, Vulvovaginal; Dise | 2022 |
Activity of Novel Ultrashort Cyclic Lipopeptides against Biofilm of
Topics: Animals; Anti-Bacterial Agents; Biofilms; Candida; Candida albicans; Candidiasis, Vulvovaginal; Dise | 2022 |
Activity of Novel Ultrashort Cyclic Lipopeptides against Biofilm of
Topics: Animals; Anti-Bacterial Agents; Biofilms; Candida; Candida albicans; Candidiasis, Vulvovaginal; Dise | 2022 |
Activity of Novel Ultrashort Cyclic Lipopeptides against Biofilm of
Topics: Animals; Anti-Bacterial Agents; Biofilms; Candida; Candida albicans; Candidiasis, Vulvovaginal; Dise | 2022 |
Activity of Novel Ultrashort Cyclic Lipopeptides against Biofilm of
Topics: Animals; Anti-Bacterial Agents; Biofilms; Candida; Candida albicans; Candidiasis, Vulvovaginal; Dise | 2022 |
Lycopene, Mesoporous Silica Nanoparticles and Their Association: A Possible Alternative against Vulvovaginal Candidiasis?
Topics: Aged; Antifungal Agents; Candida; Candida albicans; Candidiasis, Vulvovaginal; Female; Fluconazole; | 2022 |
Lycopene, Mesoporous Silica Nanoparticles and Their Association: A Possible Alternative against Vulvovaginal Candidiasis?
Topics: Aged; Antifungal Agents; Candida; Candida albicans; Candidiasis, Vulvovaginal; Female; Fluconazole; | 2022 |
Lycopene, Mesoporous Silica Nanoparticles and Their Association: A Possible Alternative against Vulvovaginal Candidiasis?
Topics: Aged; Antifungal Agents; Candida; Candida albicans; Candidiasis, Vulvovaginal; Female; Fluconazole; | 2022 |
Lycopene, Mesoporous Silica Nanoparticles and Their Association: A Possible Alternative against Vulvovaginal Candidiasis?
Topics: Aged; Antifungal Agents; Candida; Candida albicans; Candidiasis, Vulvovaginal; Female; Fluconazole; | 2022 |
Antifungal synergistic effects and anti-biofilm formation activities of some bioactive 2,3-dihydro-1,5-benzoxazepine derivatives.
Topics: Antifungal Agents; Antioxidants; Biofilms; Candida albicans; Candidiasis, Vulvovaginal; Female; Fluc | 2022 |
New Antifungals for Vulvovaginal Candidiasis: What Is Their Role?
Topics: Antifungal Agents; Candida albicans; Candidiasis, Vulvovaginal; Drug Resistance, Fungal; Female; Flu | 2023 |
Vaginal Candida albicans: High Frequency of in Vitro Fluconazole Resistance in a Select Population-A Brief Note.
Topics: Antifungal Agents; Candida albicans; Candidiasis, Vulvovaginal; Female; Fluconazole; Humans; Microbi | 2023 |
Fluconazole-Resistant Candida albicans Vaginal Infections at a Referral Center and Treated With Boric Acid.
Topics: Aged; Antifungal Agents; Candida albicans; Candidiasis, Vulvovaginal; Female; Fluconazole; Humans; R | 2023 |
[Mechanism of n-butanol alcohol extract of Baitouweng Decoction in treatment of vulvovaginal candidiasis based on negative regulation of NLRP3 inflammasome via PKCδ/NLRC4/IL-1Ra axis].
Topics: 1-Butanol; Animals; Calcium-Binding Proteins; Candida albicans; Candidiasis, Vulvovaginal; Cytokines | 2023 |
Combination of Farnesol with Common Antifungal Drugs: Inhibitory Effect against
Topics: Antifungal Agents; Azoles; Candida; Candida albicans; Candidiasis, Vulvovaginal; Farnesol; Female; F | 2023 |
Fluconazole and propolis co-encapsulated in chitosan nanoparticles for the treatment of vulvovaginal candidiasis in a murine model.
Topics: Animals; Antifungal Agents; Candida albicans; Candidiasis, Vulvovaginal; Chitosan; Disease Models, A | 2023 |
Selected
Topics: Antifungal Agents; Candida albicans; Candidiasis, Vulvovaginal; Female; Fluconazole; Humans; Microbi | 2023 |
Designed Antimicrobial Peptides for Recurrent Vulvovaginal Candidiasis Treatment.
Topics: Animals; Antifungal Agents; Antimicrobial Cationic Peptides; Biofilms; Candida; Candidiasis, Vulvova | 2019 |
Mrr2 mutations and upregulation are associated with increased fluconazole resistance in Candida albicans isolates from patients with vulvovaginal candidiasis.
Topics: Adult; Antifungal Agents; Candida albicans; Candidiasis, Vulvovaginal; Drug Resistance, Fungal; Fema | 2020 |
Prognosis and Long-Term Outcome of Women With Idiopathic Recurrent Vulvovaginal Candidiasis Caused by Candida albicans.
Topics: Adolescent; Adult; Antifungal Agents; Candida albicans; Candidiasis, Vulvovaginal; Drug Resistance, | 2020 |
Prevalence and antifungal susceptibility of Candida albicans causing vaginal discharge among pregnant women in Lebanon.
Topics: Adult; Amphotericin B; Antifungal Agents; Candida albicans; Candida glabrata; Candidiasis, Vulvovagi | 2020 |
Effect of progesterone on Candida albicans biofilm formation under acidic conditions: A transcriptomic analysis.
Topics: Acids; Antifungal Agents; Biofilms; Candida albicans; Candidiasis, Vulvovaginal; Female; Fluconazole | 2020 |
Vaginal pH and microbiota during fluconazole maintenance treatment for recurrent vulvovaginal candidosis (RVVC).
Topics: Acute Disease; Adolescent; Adult; Antifungal Agents; Bacteria; Candida; Candidiasis, Vulvovaginal; D | 2020 |
[Analysis of homology and drug sensitivity of vaginal isolates of 10 patients with recurrent vulvovaginal candidiasis in recurrent episodes].
Topics: Antifungal Agents; Candida albicans; Candidiasis, Vulvovaginal; Drug Resistance, Fungal; Female; Flu | 2020 |
Anidulafungin treatment for fluconazole-resistant
Topics: Adult; Anidulafungin; Antifungal Agents; Azoles; Candida albicans; Candidiasis, Vulvovaginal; Drug R | 2021 |
Prevalence of vulvovaginal candidiasis among pregnant women in the Ho municipality, Ghana: species identification and antifungal susceptibility of Candida isolates.
Topics: Adolescent; Adult; Antifungal Agents; Candida; Candida albicans; Candida glabrata; Candida parapsilo | 2020 |
Oral fluconazole use in the first trimester and risk of congenital malformations: population based cohort study.
Topics: Abnormalities, Drug-Induced; Administration, Oral; Adult; Antifungal Agents; Candidiasis, Vulvovagin | 2020 |
Proposal for a microcosm biofilm model for the study of vulvovaginal candidiasis.
Topics: Antifungal Agents; Biofilms; Candida albicans; Candidiasis, Vulvovaginal; Female; Fluconazole; Human | 2020 |
Anti-biofilm activity of chlorhexidine digluconate against Candida albicans vaginal isolates.
Topics: Adult; Antifungal Agents; Biofilms; Candida; Candida albicans; Candidiasis; Candidiasis, Vulvovagina | 2020 |
Bullous fixed drug eruption induced by fluconazole: Importance of multi-site lesional patch testing.
Topics: Administration, Oral; Adult; Antifungal Agents; Candidiasis, Vulvovaginal; Drug Eruptions; Female; F | 2021 |
Prophylactic and Therapeutic Role of Vitamin D3 in Combination with Fluconazole Against Vaginal Candidiasis in a Murine Model.
Topics: Animals; Antifungal Agents; Candidiasis, Vulvovaginal; Cholecalciferol; Disease Models, Animal; Fema | 2021 |
Treatment methods for vulvovaginal candidiasis in pregnancy.
Topics: Antifungal Agents; Candida albicans; Candidiasis, Vulvovaginal; Female; Fluconazole; Humans; Pregnan | 2021 |
Topics: Antifungal Agents; Candida; Candidiasis, Vulvovaginal; Drug Resistance, Fungal; Female; Fluconazole; | 2021 |
Comment on "Maternal use of fluconazole and congenital malformations in the progeny: A meta-analysis of the literature".
Topics: Antifungal Agents; Candidiasis, Vulvovaginal; Female; Fluconazole; Humans | 2021 |
Analysis of Biofilm-Related Genes and Antifungal Susceptibility Pattern of Vaginal
Topics: Adult; Amphotericin B; Antifungal Agents; Biofilms; Biomass; Candida albicans; Candida glabrata; Can | 2021 |
Evaluation of the antifungal activity of an ebselen-loaded nanoemulsion in a mouse model of vulvovaginal candidiasis.
Topics: Animals; Antifungal Agents; Candida albicans; Candidiasis, Vulvovaginal; Disease Models, Animal; Emu | 2021 |
Non-response to fluconazole maintenance treatment (ReCiDiF regimen) for recurrent vulvovaginal candidosis is not related to impaired glucose metabolism.
Topics: Adult; Antifungal Agents; Blood Glucose; Body Mass Index; Candidiasis, Vulvovaginal; Diabetes Compli | 2017 |
Biofilms Formed by Isolates from Recurrent Vulvovaginal Candidiasis Patients Are Heterogeneous and Insensitive to Fluconazole.
Topics: Antifungal Agents; Biofilms; Candida albicans; Candida glabrata; Candida parapsilosis; Candida tropi | 2017 |
In vitro susceptibility of Candida albicans clinical isolates to eight antifungal agents in Ouagadougou (Burkina Faso).
Topics: Adult; Amphotericin B; Antifungal Agents; Burkina Faso; Candida albicans; Candidiasis; Candidiasis, | 2017 |
Prevalence and antifungal susceptibility of Candida species in a tertiary care hospital in Islamabad, Pakistan.
Topics: Adolescent; Adult; Amphotericin B; Antifungal Agents; Candida; Candida albicans; Candida glabrata; C | 2017 |
Nanolipid Gel of an Antimycotic Drug for Treating Vulvovaginal Candidiasis-Development and Evaluation.
Topics: Animals; Antifungal Agents; Candida albicans; Candidiasis, Vulvovaginal; Drug Evaluation, Preclinica | 2018 |
Is non-response to fluconazole maintenance therapy for recurrent Candida vaginitis related to sensitization to atopic reactions?
Topics: Adult; Candida albicans; Candidiasis, Vulvovaginal; Female; Fluconazole; Humans; Hypersensitivity, I | 2018 |
Reduced Antifungal Susceptibility of Vulvovaginal Candida Species at Normal Vaginal pH Levels: Clinical Implications.
Topics: Antifungal Agents; Candida; Candidiasis, Vulvovaginal; Female; Fluconazole; Humans; Hydrogen-Ion Con | 2018 |
Anticandidal synergistic activity of Ocimum sanctum and fluconazole of azole resistance strains of clinical isolates.
Topics: Antifungal Agents; Candida albicans; Candidiasis, Vulvovaginal; Drug Resistance, Fungal; Female; Flu | 2018 |
Antifungal susceptibilities, in vitro production of virulence factors and activities of ceragenins against Candida spp. isolated from vulvovaginal candidiasis.
Topics: Antifungal Agents; Biofilms; Candida; Candida albicans; Candida glabrata; Candida parapsilosis; Cand | 2019 |
Vulvovaginal candidiasis: species distribution of Candida and their antifungal susceptibility pattern.
Topics: Adolescent; Adult; Antifungal Agents; Candida albicans; Candidiasis, Vulvovaginal; Caspofungin; Cros | 2018 |
Prevalence and antifungal susceptibility of Candida species among pregnant women attending a school maternity at Natal, Brazil.
Topics: Adolescent; Adult; Amphotericin B; Antifungal Agents; Brazil; Candida; Candida glabrata; Candidiasis | 2018 |
Long-Term Outcomes of Women With Recurrent Vulvovaginal Candidiasis After a Course of Maintenance Antifungal Therapy.
Topics: Adult; Aged; Antifungal Agents; Candida albicans; Candidiasis, Vulvovaginal; Female; Fluconazole; Fo | 2018 |
Effect of pea protein plus grape seed dry extract on a murine model of Candida albicans induced vaginitis.
Topics: Animals; Antifungal Agents; Biofilms; Candida albicans; Candidiasis, Vulvovaginal; Disease Models, A | 2018 |
Is multiple-site colonization with Candida spp. related to inadequate response to individualized fluconazole maintenance therapy in women with recurrent Candida vulvovaginitis?
Topics: Adult; Aged; Antifungal Agents; Candida; Candidiasis, Vulvovaginal; Drug Resistance, Fungal; Female; | 2018 |
Associations between low- and high-dose oral fluconazole and pregnancy outcomes: 3 nested case-control studies.
Topics: Abortion, Spontaneous; Administration, Oral; Adolescent; Adult; Antifungal Agents; Candidiasis, Vulv | 2019 |
Severe candidal balanoposthitis on concurrent treatment with secukinumab and the antidiabetic agent empagliflozin (sodium-glucose cotransporter 2 inhibitor - SGLT2-inhibitor).
Topics: Administration, Oral; Angioedema; Antibodies, Monoclonal, Humanized; Antifungal Agents; Benzhydryl C | 2019 |
Antifungal (oral and vaginal) therapy for recurrent vulvovaginal candidiasis: a systematic review protocol.
Topics: Administration, Intravaginal; Administration, Oral; Antifungal Agents; Candidiasis, Vulvovaginal; Dr | 2019 |
Candida nivariensis as an etiologic agent of vulvovaginal candidiasis in a tertiary care hospital of New Delhi, India.
Topics: Adult; Amphotericin B; Antifungal Agents; Candida; Candidiasis, Vulvovaginal; DNA, Fungal; Drug Resi | 2013 |
Alcohol dehydrogenase I expression correlates with CDR1, CDR2 and FLU1 expression in Candida albicans from patients with vulvovaginal candidiasis.
Topics: Alcohol Dehydrogenase; ATP-Binding Cassette Transporters; Candida albicans; Candidiasis, Vulvovagina | 2013 |
Efficacy of itraconazole versus fluconazole in vaginal candidiasis.
Topics: Adolescent; Adult; Antifungal Agents; Candidiasis, Vulvovaginal; Chi-Square Distribution; Female; Fl | 2012 |
Frequency of vagınal candida colonization and relationship between metabolic parameters in children with type 1 diabetes mellitus.
Topics: Adolescent; Antifungal Agents; Blood Glucose; Candida; Candidiasis, Vulvovaginal; Carrier State; Chi | 2013 |
Oral fluconazole and vulvovaginal candidiasis: prevention is not always better than cure.
Topics: Administration, Oral; Antifungal Agents; Candidiasis, Vulvovaginal; Female; Fluconazole; Humans | 2013 |
Prevalence of Candida albicans and non-albicans isolates from vaginal secretions: comparative evaluation of colonization, vaginal candidiasis and recurrent vaginal candidiasis in diabetic and non-diabetic women.
Topics: Adolescent; Adult; Aged; Antifungal Agents; Brazil; Candida; Candida albicans; Candidiasis, Vulvovag | 2014 |
Anti-Candida activity of fluoxetine alone and combined with fluconazole: a synergistic action against fluconazole-resistant strains.
Topics: Antifungal Agents; Candida; Candidiasis, Vulvovaginal; Drug Resistance, Fungal; Drug Synergism; Drug | 2014 |
Periodic presumptive treatment for women with prevalent vaginal infections: secondary analysis of data from a randomized controlled trial.
Topics: Adult; Anti-Infective Agents; Candidiasis, Vulvovaginal; Chemoprevention; Female; Fluconazole; Human | 2014 |
Vulvovaginal candidiasis: species distribution, fluconazole resistance and drug efflux pump gene overexpression.
Topics: Antifungal Agents; ATP-Binding Cassette Transporters; Candida; Candidiasis, Vulvovaginal; Drug Resis | 2014 |
Candida parapsilosis sensu stricto and the closely related species Candida orthopsilosis and Candida metapsilosis in vulvovaginal candidiasis.
Topics: Adult; Antifungal Agents; Candida; Candidiasis, Vulvovaginal; Clotrimazole; Drug Resistance, Fungal; | 2015 |
Vaginal nystatin versus oral fluconazole for the treatment for recurrent vulvovaginal candidiasis.
Topics: Administration, Intravaginal; Administration, Oral; Adolescent; Adult; Antifungal Agents; Candida al | 2015 |
[Yeast species in vulvovaginitis candidosa].
Topics: Administration, Intravaginal; Administration, Oral; Adult; Aged; Anti-Bacterial Agents; Antifungal A | 2015 |
Hymenal stenosis and fibrosis in two adult women.
Topics: Antifungal Agents; Candidiasis, Vulvovaginal; Constriction, Pathologic; Dyspareunia; Female; Fibrosi | 2015 |
Itraconazole-resistant Candida auris with phospholipase, proteinase and hemolysin activity from a case of vulvovaginitis.
Topics: Adult; Antifungal Agents; Candida; Candidiasis, Vulvovaginal; DNA, Fungal; DNA, Ribosomal Spacer; Dr | 2015 |
Non-albicans Candida Vulvovaginitis: Treatment Experience at a Tertiary Care Vaginitis Center.
Topics: Adult; Aged; Antifungal Agents; Boric Acids; Candida; Candidiasis, Vulvovaginal; Female; Fluconazole | 2016 |
Efficacy of the clinical agent VT-1161 against fluconazole-sensitive and -resistant Candida albicans in a murine model of vaginal candidiasis.
Topics: Animals; Antifungal Agents; Candida albicans; Candidiasis, Vulvovaginal; Female; Fluconazole; Mice; | 2015 |
Combination of Estrogen and Immunosuppressive Agents to Establish a Mouse Model of Candidiasis with Concurrent Oral and Vaginal Mucosal Infection.
Topics: Animals; Antifungal Agents; Candida; Candidiasis, Oral; Candidiasis, Vulvovaginal; Colony Count, Mic | 2016 |
Fluconazole exposure during pregnancy.
Topics: Abnormalities, Drug-Induced; Antifungal Agents; Candidiasis, Vulvovaginal; Female; Fluconazole; Huma | 2015 |
Association Between Use of Oral Fluconazole During Pregnancy and Risk of Spontaneous Abortion and Stillbirth.
Topics: Abortion, Spontaneous; Administration, Oral; Adult; Antifungal Agents; Candidiasis, Vulvovaginal; Ca | 2016 |
[Pulsatilla decoction inhibits vulvovaginal Candida albicans proliferation and reduces inflammatory cytokine levels in vulvovaginal candidiasis mice].
Topics: Animals; Antifungal Agents; Candida albicans; Candidiasis, Vulvovaginal; Cytokines; Dose-Response Re | 2016 |
[Identification and in vitro antifungal susceptibility of vaginal Candida spp. isolates to fluconazole, clotrimazole and nystatin].
Topics: Antifungal Agents; Candida; Candidiasis, Vulvovaginal; Clotrimazole; Drug Resistance, Fungal; Female | 2016 |
Quality of life in patients with chronic vulvovaginal candidiasis: A before and after study on the impact of oral fluconazole therapy.
Topics: Administration, Oral; Adult; Antifungal Agents; Candidiasis, Vulvovaginal; Chronic Disease; Female; | 2017 |
Species Distribution and In Vitro Antifungal Susceptibility of Vulvovaginal Candida Isolates in China.
Topics: Antifungal Agents; Candida; Candidiasis, Vulvovaginal; China; Clotrimazole; Drug Resistance, Fungal; | 2016 |
Management of chronic vulvovaginal candidiasis: a long term retrospective study.
Topics: Administration, Oral; Adolescent; Adult; Antifungal Agents; Candidiasis, Vulvovaginal; Chronic Disea | 2017 |
Oral fluconazole is often used during pregnancy in the treatment of vulvovaginal candidiasis despite safety concerns to the fetus.
Topics: Administration, Oral; Antifungal Agents; Candidiasis, Vulvovaginal; Female; Fetus; Fluconazole; Huma | 2016 |
Candida duobushaemulonii: an emerging rare pathogenic yeast isolated from recurrent vulvovaginal candidiasis in Brazil.
Topics: Antifungal Agents; Brazil; Candida; Candidiasis, Vulvovaginal; Drug Resistance, Fungal; Female; Fluc | 2016 |
Genotyping and Persistence of Candida albicans from Pregnant Women with Vulvovaginal Candidiasis.
Topics: Administration, Topical; Adolescent; Adult; Antifungal Agents; Candida albicans; Candidiasis, Vulvov | 2017 |
Quercetin Assists Fluconazole to Inhibit Biofilm Formations of Fluconazole-Resistant Candida Albicans in In Vitro and In Vivo Antifungal Managements of Vulvovaginal Candidiasis.
Topics: Animals; Antifungal Agents; Bacterial Adhesion; Biofilms; Candida albicans; Candidiasis, Vulvovagina | 2016 |
Chronic vulvovaginal candidiasis in patients using a levonorgestrel-containing intrauterine device.
Topics: Adult; Antifungal Agents; Candidiasis, Vulvovaginal; Chronic Disease; Contraceptive Agents, Female; | 2018 |
Elevated nitric oxide in recurrent vulvovaginal candidiasis - association with clinical findings.
Topics: Adolescent; Adult; Antifungal Agents; Candidiasis, Vulvovaginal; Case-Control Studies; Female; Fluco | 2017 |
Antifungal peptides: a potential new class of antifungals for treating vulvovaginal candidiasis caused by fluconazole-resistant Candida albicans.
Topics: Agar; Amino Acid Sequence; Antifungal Agents; Antimicrobial Cationic Peptides; Candida albicans; Can | 2017 |
Mannose-binding lectin gene polymorphism and resistance to therapy in women with recurrent vulvovaginal candidiasis.
Topics: Adult; Antifungal Agents; Candidiasis, Vulvovaginal; Case-Control Studies; Codon; Drug Resistance; F | 2008 |
[Flucoric--reliability in the treatment of fungal infections].
Topics: Antifungal Agents; Candidiasis, Vulvovaginal; Drug Administration Schedule; Female; Fluconazole; Hum | 2008 |
Individualized decreasing-dose maintenance fluconazole regimen for recurrent vulvovaginal candidiasis (ReCiDiF trial).
Topics: Administration, Oral; Adolescent; Adult; Antifungal Agents; Candidiasis, Vulvovaginal; Dose-Response | 2008 |
Reduced fluconazole susceptibility of Candida albicans isolates in women with recurrent vulvovaginal candidiasis: effects of long-term fluconazole therapy.
Topics: Adult; Antifungal Agents; Candida albicans; Candidiasis, Vulvovaginal; Drug Resistance, Fungal; Fema | 2009 |
[Fluconazole for recurrent vulvovaginal candidiasis].
Topics: Antifungal Agents; Candidiasis, Vulvovaginal; Child, Preschool; Female; Fluconazole; Humans | 2009 |
Trends in frequency and in vitro antifungal susceptibility patterns of Candida isolates from women attending the STD outpatients clinic of a tertiary care hospital in Northern Italy during the years 2002-2007.
Topics: Antifungal Agents; Candida; Candidiasis, Vulvovaginal; Drug Resistance, Fungal; Female; Fluconazole; | 2009 |
Biofilm formation on intrauterine devices in patients with recurrent vulvovaginal candidiasis.
Topics: Adult; Amphotericin B; Antifungal Agents; Biofilms; Candida albicans; Candidiasis, Vulvovaginal; Fem | 2010 |
[Combined single-day treatment in acute vulvovaginal candidosis].
Topics: Administration, Oral; Administration, Topical; Antifungal Agents; Candida; Candidiasis, Vulvovaginal | 2009 |
In vitro fluconazole and nystatin susceptibility and clinical outcome in complicated vulvovaginal candidosis.
Topics: Adult; Antifungal Agents; Candida; Candidiasis, Vulvovaginal; Drug Resistance, Fungal; Female; Fluco | 2011 |
The effect of antifungal treatment on the vaginal flora of women with vulvo-vaginal yeast infection with or without bacterial vaginosis.
Topics: Administration, Oral; Antifungal Agents; Bacteria; Candidiasis, Vulvovaginal; Female; Fluconazole; H | 2011 |
Molecular typing and in vitro fluconazole susceptibility of Candida species isolated from diabetic and nondiabetic women with vulvovaginal candidiasis in India.
Topics: Antifungal Agents; Candida albicans; Candida glabrata; Candidiasis, Vulvovaginal; Diabetes Complicat | 2011 |
In vivo activity of Sapindus saponaria against azole-susceptible and -resistant human vaginal Candida species.
Topics: Animals; Antifungal Agents; Azoles; Brazil; Candida albicans; Candida glabrata; Candidiasis, Vulvova | 2011 |
Recurrent vulvovaginal candidosis: focus on the vulva.
Topics: Administration, Oral; Administration, Topical; Antifungal Agents; Biopsy; Candida albicans; Candidia | 2011 |
Antifungal efficacy of propolis against fluconazole-resistant Candida glabrata isolates obtained from women with recurrent vulvovaginal candidiasis.
Topics: Antifungal Agents; Candida glabrata; Candidiasis, Vulvovaginal; Drug Resistance, Fungal; Female; Flu | 2011 |
FPIN’s clinical inquiries: treatment of recurrent vulvovaginal candidiasis.
Topics: Administration, Intravaginal; Administration, Oral; Antifungal Agents; Candidiasis, Vulvovaginal; Cl | 2011 |
Rapid onset of iatrogenic adrenal insufficiency in a patient with cystic fibrosis-related liver disease treated with inhaled corticosteroids and a moderate CYP3A4 inhibitor.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenal Insufficiency; Androstadienes; Anti-Ast | 2011 |
Efficacy of fluconazole and nystatin in the treatment of vaginal Candida species.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifungal Agents; Brazil; Candida albicans; Candida gla | 2012 |
Yeast vaginitis during pregnancy: susceptibility testing of 13 antifungal drugs and boric acid and the detection of four virulence factors.
Topics: Adolescent; Adult; Amphotericin B; Animals; Antifungal Agents; Boric Acids; Candida albicans; Candid | 2012 |
[The statement of Polish Gynecological Society Experts on the etiology and treatment of recurrent vulvovaginal candidiasis].
Topics: Antifungal Agents; Candida; Candidiasis, Vulvovaginal; Female; Fluconazole; Humans | 2011 |
Therapeutic use of a cationic antimicrobial peptide from the spider Acanthoscurria gomesiana in the control of experimental candidiasis.
Topics: Animals; Antifungal Agents; Antimicrobial Cationic Peptides; Candida albicans; Candidiasis; Candidia | 2012 |
[The Polish Gynecological Society Expert Committee recomendations regarding application of fluconazole in the treatment of vulvovaginal candidiasis].
Topics: Acute Disease; Administration, Topical; Antifungal Agents; Candida; Candidiasis, Vulvovaginal; Chron | 2012 |
[Efficacy of voriconazole treatment in chronic vulvovaginal candidosis due to Candida glabrata].
Topics: Adult; Antifungal Agents; Candida glabrata; Candidiasis, Vulvovaginal; Cesarean Section; Drug Evalua | 2013 |
In vitro assessment of gentian violet anti- candida activity.
Topics: Antifungal Agents; Candida; Candida albicans; Candida tropicalis; Candidiasis, Vulvovaginal; Female; | 2012 |
Fixed drug eruption caused by ornidazole and fluconazole but not isoconazole, itraconazole, ketoconazole and metronidazole.
Topics: Adult; Antifungal Agents; Antiprotozoal Agents; Candidiasis, Vulvovaginal; Drug Eruptions; Female; F | 2013 |
Fluconazole-resistant Candida albicans vulvovaginitis.
Topics: Adult; Antifungal Agents; Candida albicans; Candidiasis, Vulvovaginal; Drug Resistance, Fungal; Fema | 2012 |
Vulvovaginitis due to fluconazole resistant Candida albicans following self treatment with non-prescribed triazoles.
Topics: Adult; Antifungal Agents; Candidiasis, Vulvovaginal; Drug Resistance, Fungal; Female; Fluconazole; H | 2002 |
Prevalence of vulvovaginal candidiasis and susceptibility to fluconazole in women.
Topics: Adult; Aged; Antifungal Agents; Candida; Candidiasis, Vulvovaginal; Contraceptives, Oral; Estrogen R | 2002 |
CDC releases 2002 guidelines for treating STDs: Part I. Diseases characterized by vaginal discharge and PID.
Topics: Anti-Infective Agents; Candidiasis, Vulvovaginal; Female; Fluconazole; Humans; Metronidazole; Pelvic | 2002 |
Comparison of microdilution and disc diffusion methods in assessing the in vitro activity of fluconazole and Melaleuca alternifolia (tea tree) oil against vaginal Candida isolates.
Topics: Anti-Infective Agents, Local; Antifungal Agents; Candida; Candidiasis, Vulvovaginal; Drug Resistance | 2002 |
Fluconazole susceptibility of vaginal isolates obtained from women with complicated Candida vaginitis: clinical implications.
Topics: Candida albicans; Candidiasis, Vulvovaginal; Female; Fluconazole; Humans; Microbial Sensitivity Test | 2003 |
In vitro and in vivo activity of tea tree oil against azole-susceptible and -resistant human pathogenic yeasts.
Topics: Animals; Antifungal Agents; Azoles; Candida albicans; Candidiasis, Vulvovaginal; Drug Resistance, Fu | 2003 |
[Use of fluconazole during pregnancy].
Topics: Antifungal Agents; Candidiasis, Vulvovaginal; Dose-Response Relationship, Drug; Female; Fluconazole; | 2003 |
Fluconazole and itraconazole susceptibility of vaginal yeast isolates from Slovakia.
Topics: Antifungal Agents; Candida; Candida albicans; Candida glabrata; Candidiasis, Vulvovaginal; Drug Resi | 2004 |
Fluconazole resistant non-albicans vaginal yeast in HIV seronegative women with vaginal discharge in Pune, India.
Topics: Antifungal Agents; Candidiasis, Vulvovaginal; Drug Resistance, Fungal; Female; Fluconazole; HIV Sero | 2004 |
Chronic vulvovaginal candidiasis.
Topics: Administration, Oral; Antifungal Agents; Candidiasis, Vulvovaginal; Chronic Disease; Drug Administra | 2004 |
Trends in prescribing for vulvovaginal candidiasis in the United States.
Topics: Administration, Intravaginal; Adolescent; Adult; Antifungal Agents; Candidiasis, Vulvovaginal; Drug | 2005 |
[Three years experience of using mycosyst].
Topics: Abortion, Therapeutic; Adult; Antifungal Agents; Candidiasis, Vulvovaginal; Female; Fluconazole; Hum | 2004 |
[New study shows probiotics ineffective in prevention of post-antibiotic vaginal candidiasis].
Topics: Administration, Intravaginal; Administration, Oral; Anti-Bacterial Agents; Antifungal Agents; Candid | 2004 |
Chronic vulvovaginal candidiasis.
Topics: Antifungal Agents; Candidiasis, Vulvovaginal; Data Interpretation, Statistical; Drug Administration | 2004 |
Chronic vulvovaginal candidiasis.
Topics: Administration, Intravaginal; Antifungal Agents; Candidiasis, Vulvovaginal; Clotrimazole; Female; Fl | 2004 |
[Study of acute vulvovaginitis in sexually active adult women, with special reference to candidosis, in patients of the Francisco J. Muñiz Infectious Diseases Hospital].
Topics: Acute Disease; Adolescent; Adult; Argentina; Candida; Candidiasis, Vulvovaginal; Carrier State; Como | 2004 |
Pattern of Candida species isolated from patients with diabetes mellitus and vulvovaginal candidiasis and their response to single dose oral fluconazole therapy.
Topics: Administration, Oral; Adult; Antifungal Agents; Candida; Candida albicans; Candida glabrata; Candidi | 2006 |
Post-menopausal recurrent vaginal candidiasis: effect of hysterectomy on response to treatment, type of colonization and recurrence rates post-treatment.
Topics: Antifungal Agents; Candida albicans; Candidiasis, Vulvovaginal; Case-Control Studies; Cohort Studies | 2005 |
[Treatment of recurrent vulvovaginal candidosis with mycosyst (fluconazole)].
Topics: Administration, Intravaginal; Administration, Oral; Adult; Antifungal Agents; Candida albicans; Cand | 2005 |
Successful treatment of refractory recurrent vaginal candidiasis with cetirizine plus fluconazole.
Topics: Adult; Anti-Allergic Agents; Antifungal Agents; Candidiasis, Vulvovaginal; Cetirizine; Female; Fluco | 2005 |
Vulvovaginal candidiasis in a Flemish patient population.
Topics: Antifungal Agents; Belgium; Candida; Candidiasis, Vulvovaginal; Drug Resistance, Fungal; Female; Flu | 2005 |
Phenotypic and genotypic evaluation of fluconazole resistance in vaginal Candida strains isolated from HIV-infected women from Brazil.
Topics: Adult; AIDS-Related Opportunistic Infections; Antifungal Agents; Brazil; Candida; Candidiasis, Vulvo | 2005 |
Single-dose fluconazole for vulvovaginal candidiasis: impact on prothrombin time in women taking warfarin.
Topics: Anticoagulants; Antifungal Agents; Candidiasis, Vulvovaginal; Female; Fluconazole; Humans; Middle Ag | 2006 |
Prevalence, susceptibility profile and proteinase production of yeasts causing vulvovaginitis in Turkish women.
Topics: Adult; Amphotericin B; Antifungal Agents; Candida; Candidiasis, Vulvovaginal; Female; Fluconazole; H | 2006 |
[Toxic epidermal necrolysis].
Topics: Administration, Oral; Administration, Topical; Adult; Antifungal Agents; Biopsy; Candidiasis, Vulvov | 2006 |
Resistance mechanisms in fluconazole-resistant Candida albicans isolates from vaginal candidiasis.
Topics: Amino Acid Sequence; Amino Acid Substitution; Antifungal Agents; Candida albicans; Candidiasis, Vulv | 2006 |
Caspofungin in the treatment of azole-refractory esophageal candidiasis in kidney transplant recipients.
Topics: Adult; Aged; Antifungal Agents; Candidiasis; Candidiasis, Vulvovaginal; Caspofungin; Cyclosporine; E | 2006 |
Vulvovaginal candidiasis from non-albicans species: retrospective study of recurrence rate after fluconazole therapy.
Topics: Adult; Aged; Antifungal Agents; Candida; Candidiasis, Vulvovaginal; Female; Fluconazole; Humans; Mid | 2006 |
In vivo activity of terpinen-4-ol, the main bioactive component of Melaleuca alternifolia Cheel (tea tree) oil against azole-susceptible and -resistant human pathogenic Candida species.
Topics: Animals; Antifungal Agents; Azoles; Candida; Candida albicans; Candidiasis, Vulvovaginal; Drug Resis | 2006 |
Therapeutic efficacy of posaconazole against isolates of Candida albicans with different susceptibilities to fluconazole in a vaginal model.
Topics: Animals; Antifungal Agents; Candida albicans; Candidiasis, Vulvovaginal; Colony Count, Microbial; Di | 2007 |
Comparison of the effects of three different anti-fungus drugs on Candida albicans of murine vaginal mucosa.
Topics: Animals; Antifungal Agents; Candidiasis, Vulvovaginal; Female; Fluconazole; Itraconazole; Mice; Mice | 2007 |
[Identification and susceptibility against fluconazole and albaconazole of 100 yeasts' strains isolated from vaginal discharge].
Topics: Adult; Antifungal Agents; Body Fluids; Candida; Candida albicans; Candida glabrata; Candidiasis, Vul | 2007 |
Increase of virulence and its phenotypic traits in drug-resistant strains of Candida albicans.
Topics: Animals; Antifungal Agents; Biofilms; Candida albicans; Candidiasis; Candidiasis, Vulvovaginal; Cell | 2008 |
Chronic fungal vaginitis: the value of cultures.
Topics: Candida; Candida albicans; Candidiasis, Vulvovaginal; Chronic Disease; Female; Fluconazole; Humans; | 1995 |
Fluconazole concentrations in breast milk.
Topics: Administration, Oral; Adult; Breast Feeding; Candidiasis, Vulvovaginal; Female; Fluconazole; Half-Li | 1995 |
Clinically significant mucosal candidiasis resistant to fluconazole treatment in patients with AIDS.
Topics: Adult; AIDS-Related Opportunistic Infections; Candida; Candidiasis, Oral; Candidiasis, Vulvovaginal; | 1994 |
New indication for oral fluconazole.
Topics: Administration, Oral; Candidiasis, Vulvovaginal; Female; Fluconazole; Humans | 1995 |
Safety of fluconazole in the treatment of vaginal candidiasis. A prescription-event monitoring study, with special reference to the outcome of pregnancy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Candidiasis, Vulvovaginal; Child; Child, Preschool; Drug | 1994 |
Oral fluconazole for vaginal candidiasis.
Topics: Administration, Oral; Candidiasis, Vulvovaginal; Clinical Trials as Topic; Female; Fluconazole; Huma | 1994 |
Sch 39304, a new antifungal agent: oral and topical treatment of vaginal and superficial infections.
Topics: Administration, Oral; Administration, Topical; Animals; Antifungal Agents; Candidiasis, Vulvovaginal | 1993 |
Management of persistent vulvo vaginal candidosis due to azole-resistant Candida glabrata.
Topics: Administration, Oral; Administration, Topical; Adult; Antifungal Agents; Candidiasis, Vulvovaginal; | 1993 |
Symptomatic vulvovaginitis due to fluconazole-resistant Candida albicans in a female who was not infected with human immunodeficiency virus.
Topics: Adult; Antifungal Agents; Boric Acids; Candidiasis, Vulvovaginal; Drug Resistance, Microbial; Female | 1996 |
Prospective assessment of pregnancy outcomes after first-trimester exposure to fluconazole.
Topics: Adult; Antifungal Agents; Candidiasis, Vulvovaginal; Cohort Studies; Female; Fluconazole; Humans; Pr | 1996 |
Fluconazole treatment for vulvovaginal candidiasis during pregnancy.
Topics: Adult; Antifungal Agents; Candidiasis, Vulvovaginal; Female; Fluconazole; Humans; Infant, Newborn; M | 1997 |
Congenital anomalies and fluconazole.
Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Animals; Antifungal Agents; Candidiasis, Vulvo | 1997 |
Single-dose systemic oral fluconazole for the treatment of vaginal candidiasis.
Topics: Administration, Oral; Adult; Antifungal Agents; Attitude of Health Personnel; Candidiasis, Vulvovagi | 1997 |
Successful use of boric acid to control azole-refractory Candida vaginitis in a woman with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Administration, Intravaginal; Adult; Antifungal Agents; Boric Ac | 1997 |
Weekly fluconazole for preventing mucosal candidiasis in HIV infection.
Topics: AIDS-Related Opportunistic Infections; Antifungal Agents; Candidiasis, Oral; Candidiasis, Vulvovagin | 1997 |
Diflucan: an easy-to-swallow yeast infection treatment.
Topics: Antifungal Agents; Candidiasis, Vulvovaginal; Drug Costs; Female; Fluconazole; Humans; Self Medicati | 1997 |
Clonal and spontaneous origins of fluconazole resistance in Candida albicans.
Topics: AIDS-Related Opportunistic Infections; Antifungal Agents; Candida albicans; Candidiasis; Candidiasis | 2000 |
Therapeutic experience with fluconazole in the treatment of fungal infections in diabetic patients.
Topics: Adolescent; Adult; Antifungal Agents; Candidiasis, Oral; Candidiasis, Vulvovaginal; Diabetes Complic | 1999 |
The evolution of Candida species and fluconazole susceptibility among oral and vaginal isolates recovered from human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women.
Topics: Adult; AIDS-Related Opportunistic Infections; Antifungal Agents; Candida; Candida albicans; Candidia | 2001 |
Determination of minumum inhibitory concentrations of Candida species isolated from vaginal swab specimens by using broth macrodilution and E-test.
Topics: Amphotericin B; Antifungal Agents; Candida; Candidiasis, Vulvovaginal; Female; Fluconazole; Humans; | 2001 |
Fluconazole prevents yeast infections in women with HIV.
Topics: AIDS-Related Opportunistic Infections; Antifungal Agents; Candidiasis, Oral; Candidiasis, Vulvovagin | 1996 |
Fungal infection overview.
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Blastomycosis; Candidiasis | 1995 |
An investigation into the pathogenesis of vulvo-vaginal candidosis.
Topics: Adult; Antifungal Agents; Candida albicans; Candidiasis, Vulvovaginal; Clotrimazole; Drug Resistance | 2001 |
Prevalence of vaginal colonization by drug-resistant Candida species in college-age women with previous exposure to over-the-counter azole antifungals.
Topics: Adult; Antifungal Agents; Azoles; Candidiasis, Vulvovaginal; Cross-Sectional Studies; Drug Resistanc | 2001 |
[Modern treatment of vaginal mycosis in adolescence].
Topics: Administration, Oral; Adolescent; Antifungal Agents; Candidiasis, Vulvovaginal; Child; Female; Fluco | 2001 |
[Treatment of mycotic vaginitis with Fungolon].
Topics: Administration, Oral; Adolescent; Adult; Antifungal Agents; Candidiasis, Vulvovaginal; Female; Fluco | 2001 |
Vulvovaginal candidiasis refractory to treatment with fluconazole.
Topics: Adult; Candidiasis, Vulvovaginal; Drug Resistance, Microbial; Female; Fertilization in Vitro; Flucon | 1992 |
Angio-oedema after fluconazole.
Topics: Adult; Candidiasis, Vulvovaginal; Edema; Female; Fluconazole; Humans; Mouth Diseases; Product Survei | 1991 |
[The treatment of vaginal candidiasis with a single oral dose of fluconazole].
Topics: Acute Disease; Administration, Oral; Adult; Candidiasis, Vulvovaginal; Drug Evaluation; Female; Fluc | 1991 |
Persistent Candida intertrigo treated with fluconazole.
Topics: Candidiasis, Vulvovaginal; Female; Fluconazole; Groin; Humans; Intertrigo; Middle Aged | 1991 |
Anaphylactic reaction after oral fluconazole.
Topics: Adult; Anaphylaxis; Candidiasis, Vulvovaginal; Female; Fluconazole; Humans | 1991 |
In vivo efficacy of SM-8668 (Sch 39304), a new oral triazole antifungal agent.
Topics: Administration, Cutaneous; Administration, Oral; Animals; Antifungal Agents; Aspergillosis; Aspergil | 1990 |
Fluconazole levels in plasma and vaginal secretions of patients after a 150-milligram single oral dose and rate of eradication of infection in vaginal candidiasis.
Topics: Adult; Candidiasis, Vulvovaginal; Female; Fluconazole; Half-Life; Humans; Vagina | 1990 |
[Comparison of fluconazole and ketoconazole in the therapy of vaginal candidiasis by administration in two different oral doses].
Topics: Candidiasis, Vulvovaginal; Dose-Response Relationship, Drug; Drug Evaluation; Female; Fluconazole; H | 1990 |
Treatment of vaginal candidosis with fluconazole.
Topics: Antifungal Agents; Candidiasis, Vulvovaginal; Female; Fluconazole; Follow-Up Studies; Humans; Triazo | 1989 |
Design and evaluation of a systemically active agent, fluconazole.
Topics: Animals; Antifungal Agents; Candidiasis, Vulvovaginal; Drug Design; Female; Fluconazole; Humans; Mic | 1988 |
Fluconazole resistance in Candida glabrata.
Topics: Antifungal Agents; Bile; Candida; Candidiasis; Candidiasis, Vulvovaginal; Drug Resistance, Microbial | 1988 |
Activity of UK-49,858, a bis-triazole derivative, against experimental infections with Candida albicans and Trichophyton mentagrophytes.
Topics: Amphotericin B; Animals; Antifungal Agents; Candidiasis; Candidiasis, Vulvovaginal; Dermatomycoses; | 1985 |